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“The human genome, like the universe, is composed of only a tiny fraction of
readily understood regions. The rest – more than 98 percent – is largely shrouded
in mystery. Just as physicists probe the universe in search of dark matter and
dark energy, epigeneticists are exploring the parts of the genome outside of our
genes for various pieces of evidence that can shed light on new corners.”
— Haley Bridger, Broad Communications
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Resumen
En todos los sistemas biolo´gicos esta´n implicados procesos estoca´sticos. Hoy en
d´ıa, se sabe que la variabilidad biolo´gica es necesaria para controlar el comporta-
miento de un sistema multicelular en su conjunto, y para permitir la adaptacio´n
ra´pida a cambios en el ambiente. Se ha demostrado que la plasticidad fenot´ıpica es
clave en el funcionamiento del sistema inmunolo´gico, pero que tambie´n esta´ fuerte-
mente asociada con enfermedades, especialmente ca´ncer. Hasta el momento, se han
investigado principalmente factores gene´ticos en este contexto, y so´lo pocos estudios
se han centrado en la heterogeneidad a nivel epigeno´mico y transcripto´mico.
En el marco de dos consorcios internacionales, utilizamos los primeros conjuntos
de datos de gran escala disponibles para explorar la variabilidad biolo´gica. Desarro-
llamos nuevas estrategias anal´ıticas que combinan diferentes me´todos para medir la
variabilidad con modelos estad´ısticos bien establecidos que nos permiten conseguir
una cuantificacio´n robusta de la heterogeneidad interindividual. Estudiamos la va-
riabilidad en dos contextos biolo´gicos distintos. Primero, cuantificamos la variabili-
dad transcripcional en grandes cohortes de pacientes con leucemia linfoc´ıtica cro´nica
(LLC) y estudiamos las diferencias entre los dos subtipos principales de la enferme-
dad. Segundo, analizamos la variabilidad en la metilacio´n del ADN y la expresio´n
ge´nica en monocitos, neutro´filos y ce´lulas T obtenidos de 48 individuos sanos.
Encontramos que el subtipo ma´s agresivo de LLC muestra un aumento significa-
tivo de la heterogeneidad transcripcional interindividual. Los genes con una mayor
variabilidad en la forma agresiva de la enfermedad esta´n enriquecidos en funcio-
nes relacionadas con el ciclo celular, rutas de sen˜alizacio´n, diferenciacio´n celular, y
desarrollo. Estas observaciones indican una posible relacio´n entre la heterogeneidad
transcripcional y la progresio´n y agresividad de la enfermedad. El ana´lisis de la
variabilidad diferencial entre los tres tipos celulares ma´s abundantes del sistema
inmunolo´gico humano mostro´ que los neutro´filos tienen mayor variabilidad tanto
en sus perfiles de metilacio´n del ADN como en los de expresio´n ge´nica. Esto puede
deberse a la funcio´n de los neutro´filos como las primeras ce´lulas del sistema inmune
que migran a sitios de inflamacio´n, ya que la plasticidad epigene´tica y transcripcio-
nal son esenciales para permitir una respuesta ra´pida a cambios en el entorno.
En conjunto, los resultados de este trabajo recalcan la importancia de la varia-
bilidad epigene´tica y transcripcional en el sistema inmunolo´gico humano tanto en
condiciones sanas como enfermas, as´ı como la necesidad del desarrollo de te´cnicas
bien fundamentadas para analizar dicha variabilidad. Nuestros resultados propor-
cionan nuevos conocimientos sobre la plasticidad de las ce´lulas del sistema inmune
normales y con LLC, y a largo plazo, el estudio de la heterogeneidad a nivel epi-
geno´mico y transcripto´mico habilitara´ el desarrollo de estrategias terape´uticas diri-
gidas a modular la variabilidad en enfermedades hematopoye´ticas e inmunolo´gicas.
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Abstract
Stochastic processes are involved in every biological system. Nowadays it is well
known that biological variability is necessary to reliably control the behavior of a
multicellular system as a whole, and to enable a rapid adaptation to changes in
the environment. Phenotypic plasticity has been demonstrated to be key in the
functioning of the human immune system, but has also been strongly associated
with human diseases, especially cancer. Until now, mainly genetic factors have been
investigated in this context, and only few studies focused on heterogeneity at the
epigenomic and transcriptomic level.
Within the framework of two international genome consortia, we used the first
available large-scale datasets to explore biological variability. To this aim, we de-
veloped new analytical approaches combining different methods to measure vari-
ability with well-established statistical models to achieve a robust quantification
of interindividual heterogeneity. We studied variability at different levels in two
distinct biological contexts. First, we quantified interindividual gene expression
variation in two large cohorts of chronic lymphocytic leukemia (CLL) patients and
studied differences between the two main subtypes of the disease. Second, we an-
alyzed DNA methylation and gene expression variability across primary human
monocytes, neutrophils, and T cells derived from 48 healthy individuals.
We found that the more aggressive subtype of CLL shows significantly increased
gene expression heterogeneity across patients. Genes with increased variability in
the aggressive form of the disease are strongly enriched in functions related to the
cell cycle and show furthermore significant associations with signaling, cell differen-
tiation, and development. These observations indicate a possible relation between
heterogeneous gene expression patterns and disease progression and aggressiveness.
Analyzing differential variability across the three most abundant cell types of the
human immune system, we found that neutrophils show increased variability in
both their DNA methylation and gene expression patterns. We hypothesized that
this is due to the neutrophils’ function as the first responders in the immune system
that migrate to sites of inflammation, as epigenetic and transcriptional plasticity
are essential to enable rapid adaptation to new and changing environments.
Taken together, the results of this work highlight the importance of epigenetic
and transcriptional variability in the human immune system in health and disease,
as well as the necessity of the development of well-founded techniques to analyze this
variability. Our findings provide new insights into the plasticity of CLL and normal
immune cells, and in the long run the study of heterogeneity at the epigenomic and
transcriptomic level will empower the development of therapeutic strategies aiming
to modulate variability in hematopoietic and immunological diseases.
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Chapter 1
Introduction
1.1 Gene Expression
Every cell in a multicellular organism contains an identical copy of the genetic blueprint.
Nevertheless, cells differ dramatically in terms of shape, size and function. Different
cell types can develop because the cells synthesize different RNA and therefore different
protein molecules (Alberts et al., 2004). This is what we call gene expression, part of
the central dogma of molecular biology: “DNA makes RNA makes protein” (Crick, 1970).
More exactly, gene expression is the process by which the genetic information at the level
of a genes’ DNA sequence is transcribed into RNA to subsequently produce a functional
gene product such as a protein. It is the most fundamental level at which the genotype
(that is, the genetic makeup of a cell) gives rise to the phenotype (the set of an organism’s
observable characteristics). Thus, different types of cells may possess different gene ex-
pression profiles although they all have the same genomic sequence (Alberts et al., 2004).
This is possible due to gene regulation, forming the basic principle for cellular differen-
tiation, and for the versatility and adaptability of any organism. The cell can activate
(or upregulate) or repress (or downregulate) genes in response to a phase of the cell cy-
cle, a developmental stage, or to adapt to the environment and external signals such as
temperature changes or the treatment with a hormone (Alberts et al., 2004; Bird, 2007;
Reik, 2007).
Every single cell adjusts the speed and rate of the expression of different genes according
to its needs (see figure 1.1 for an illustrative example). The amount and timing of the
production of genes is influenced by different mechanisms that control the transcription
of DNA into RNA, described in Alberts et al. (2004), as well as Zaidi et al. (2004);
Mattick et al. (2009); Martinez & Walhout (2009), and summarized in the following two
paragraphs.
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Figure 1.1: Genes can be expressed with different efficiencies. Gene A gets transcribed and translated
at much higher rates than gene B, which allows the amount of protein A to be much greater than that
of protein B.
Figure adapted from Alberts et al. (2004).
The production of RNA is performed by the enzyme RNA polymerase which reads the
DNA to transcribe it into complementary RNA. Sections of the DNA can be more or
less accessible or even hidden from the transcriptional machinery due to its structure,
and the folding and packaging of the DNA. These local characteristics of the DNA and
consequently also the gene expression activity in these regions are furthermore heavily
influenced by epigenetic modifications, described in section 1.2. Additionally, there are
proteins that can attach themselves dynamically at regions of the DNA and thus influence
their transcription. Those proteins are called transcription factors. They can suppress or
increase the activity of a gene.
Moreover, gene transcription gets regulated through additional specificity factors, re-
pressors, activators and enhancers, which can further control when transcription occurs
and how much RNA is produced. The amount of RNA that gets finally translated into
protein is determined by translation, the process of the synthesis of RNA into proteins.
This process is regulated in a similar way as transcription, for example via translational
repressors that may inhibit the initiation of translation due to blocking the starting point.
All the above described principles of gene regulation can interact among themselves and
thereby build highly complex regulating mechanisms. The examination of gene expression
patterns on the genomic scale helps to understand the mechanisms that control multicel-
lular development and pathological cellular events, and can provide important clues to
gene function in health and disease (Schena, 2003; Rockman & Kruglyak, 2006).
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1.2 Epigenetic Modifications
The concept of epigenetics was first introduced by Waddington (1939, 1942) as “the
causal interactions between genes and their products, which bring the phenotype into
being”. Later, the term epigenetics was re-defined as heritable changes in gene expres-
sion that are not caused by alterations in the underlying DNA sequence (Holliday, 1987).
The word “epi” is of Greek origin (“εpiı”) and means “over”, “outside”, or “on top of”.
Thus, epigenetic modifications are modifications on top of the genetic material. These
modifications mark the genome using chemical compounds, which leads to alterations in
the transcriptional potential of a cell. They may last through cell divisions for the dura-
tion of a cell’s life, and they may also be inherited to subsequent generations (Bird, 2007).
Higher multicellular organisms, such as mammals or many plants, have large genomes
in which as much as half of the genes can be transcriptionally deactivated in particular
cell types (Cedar & Bergman, 2011). To achieve this, and to tightly control cellular pro-
cesses, a complex regulatory strategy is necessary (Cedar & Bergman, 2011). In contrast
with the genome, the epigenome is highly dynamic. All cells of a multicellular organism
are characterized by essentially the same genome, but many different epigenomes, which
influence which genes are active and therefore also which proteins can be produced in
every particular cell (Adams et al., 2012).
Nowadays, it is well known that epigenetic modifications are key in cellular differentiation
and development (Zhu et al., 2013; Jones, 2012), that the epigenome changes throughout
lifetime (Horvath, 2013; Heyn et al., 2012; Hannum et al., 2013), and that it serves as the
intersection between the genome and the environment (Bonasio et al., 2010; Lam et al.,
2012). Food, lifestyle changes and psychological factors such as stress have been shown to
be able to alter the epigenome, and in some studies these changes have even been shown
to be passed on to subsequent generations (Dias & Ressler, 2014; Veenendaal et al., 2013;
Morgan et al., 1999; Lam et al., 2012).
It is also very well established nowadays that epigenetic modifications are a hallmark
of cancer (Sharma et al., 2009; Timp & Feinberg, 2013; Esteller, 2008). As epigenetic
modifications are a dynamic and furthermore reversible process, they are a promising
target for therapeutic approaches (Witte et al., 2014; Baylin & Jones, 2011).
The so far best characterized epigenetic modifications are histone modifications and DNA
methylation, which will be described in more detail in the next few paragraphs, starting
with an introduction to histone modifications.
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Genomic DNA is packaged into complexes of protein and DNA, called chromatin. The
prevalent type of protein found in chromatin are histones, which condense the DNA.
The primary units of the chromatin structure, the nucleosomes, consist of an octamer of
histone proteins (H2A, H2B, H3 and H4), where the DNA is wrapped around (Lay et al.,
2015; Barski et al., 2007). The nucleosomes and the DNA form a chromatin fiber which
can be further condensed (Barski et al., 2007; Kouzarides, 2007). The organization of the
chromatin is important to maintain the balance between compaction and accessibility of
the genome (Lay et al., 2015; Li et al., 2007).
Chromatin packaging of DNA varies depending on the cell cycle stage and by local DNA
region (Lay et al., 2015). Most DNA is packaged in a closed, tightly packed chromatin
conformation, so-called heterochromatin (Kouzarides, 2007). Actively transcribed genes
however have to be highly accessible to transcription factors and other DNA binding
proteins. Such unpackaged or loose chromatin is called euchromatin and usually tran-
scriptionally active (Kouzarides, 2007). Thus, the chromatin structure influences gene
expression by making genomic regions more or less accessible for the transcription ma-
chinery of the cell via remodeling the chromatin structure and changing the density of
packaging (Kouzarides, 2007; Cedar & Bergman, 2011).
This chromatin remodeling occurs via post-translational modifications of the long amino
acid chains that make up the histone proteins. The to date most highly studied modi-
fication of histone tails is acetylation, but many additional modifications are known, for
example histone methylation, phosphorylation, ubiquitination and SUMOylation, among
others (Helin & Dhanak, 2013).
Different histone modifications have distinct regulatory functions. They can influence
for example transcriptional initiation or elongation, enhancer activity, or transcriptional
repression (Ernst et al., 2011). Furthermore, the genomic context where the histone mod-
ification occurs can lead to different effects. For example, the same modification may be
able to activate a gene when lying in the coding section of its body, while acting as a
transcriptional inhibitor when found at the gene’s promoter region (Kouzarides, 2007).
The complete set of histone modifications in a cell is known as the histone code (Strahl &
Allis, 2000), and the combination of the modifications can provide a more precise insight
into chromatin states and their regulatory functions (Jenuwein & Allis, 2001; Ernst &
Kellis, 2010).
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DNA methylation is the most widely studied and well-characterized epigenetic modifica-
tion to date (Lam et al., 2012; Jones, 2012). It is the process by which a methyl group
is added to the DNA by DNA methyltransferases (DNMTs), which can be reversed by
an antagonistic group of enzymes, DNA de-methylases (Jones, 2012). The most common
type of methylation is the conversion of cytosine into 5-methylcytosine (5mC) at CpG
dinucleotides, that is, cytosine followed by guanine in the DNA sequence, with only a
phosphate in between (Laird, 2010).
Some areas of the genome are more heavily methylated than others, and CpGs are not
evenly distributed across the genome (Laird, 2010). Regions with a high frequency of
CpG sites are called CpG islands (Jones, 2012). One of the first observations that have
been made studying DNA methylation was that when it occurs at CpG islands in the
promoter region of a gene, it has the effect of repressing gene expression, in contrast
to unmethylated promoter regions, which are associated to active transcription (Laird,
2010; Riggs, 1975; Holliday & Pugh, 1975), see figure 1.2.
Figure 1.2: DNA methylation at a gene’s promoter can silence its expression. The methylation of the
cytosine attracts capping proteins that hinder access for transcription factors that normally turn on gene
expression. When the transcription factor cannot bind to the promoter area of the gene, transcription
of RNA does not occur, and the gene is silenced.
Figure adapted from Zeisel (2007).
This is best understood for tumor suppressor genes in cancer (Esteller, 2008). However,
with the establishment of high-throughput technologies to investigate DNA methylation
profiles genome-wide, the traditional view of DNA methylation being a silencing epige-
netic mark has been challenged (Jones, 2012). The relationship between DNA promoter
methylation and gene expression has shown to be less straightforward in non-malignant
tissues, and generally, the genome-wide correlation of gene promoter methylation and
gene expression levels is often very low (Lam et al., 2012).
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Another question that has not yet been fully elucidated is the one of “what comes first?”,
DNA methylation that causes gene silencing, or the deactivation of a gene followed by
the process of methylation to add an additional layer of stability to the silencing. In
several studies, DNA methylation indeed appeared to serve as a “lock” to reinforce the
state of already inactive genes, demonstrated for example in X chromosome inactivation
and tumor suppressor genes (Lock et al., 1987; Clark & Melki, 2002; Widschwendter
et al., 2007; Ohm et al., 2007; Schlesinger et al., 2007; Jones, 2012). Others have shown
that DNA methylation can also have a more instructive role, for example in the initia-
tion of silencing in hematopoietic stem cell differentiation (Byun et al., 2009; Jones, 2012).
Traditionally, most DNA methylation studies focused on methylation occurring at CpG
islands associated to gene promoter regions, but now it has become apparent that methy-
lation located in the coding region of a body of a gene, or in intergenic regions containing
enhancers and insulators, all of which are typically present in CpG depleted regions,
exhibits crucial functions in development, differentiation and cellular viability as well
(Cedar & Bergman, 2011; Maunakea et al., 2010; Jones, 2012). Its role however is even
less clear than the one of gene promoter methylation.
Gene body methylation for example has been associated to increased expression levels,
(Jones, 2012), and there is evidence that it is involved in the control of splicing (Lev
Maor et al., 2015; Jones, 2012). Thus, the relationship between DNA methylation and
transcription is strongly dependent on the particular genomic and cellular context, and
much more complex than was thought at first sight.
Furthermore, the epigenome interacts with the genome and vice versa (Zaina et al.,
2010; Oakes et al., 2014). DNA damage for example can also cause epigenetic changes
(Kovalchuk & Baulch, 2008), and methylation alterations are known to cooperate with
mutational events in carcinogenesis (Jones, 2012; Chan et al., 2008; Baylin & Jones, 2011;
Oakes et al., 2014). The long known global hypomethylation of tumors, first reported by
Feinberg & Vogelstein (1983), has been associated to enhanced genomic instability (Jones
& Baylin, 2002; Witte et al., 2014), and it has been demonstrated for several cancers that
mutations in methyltransferases lead to loss of DNA methylation which is followed by
chromosomal instability (Qu et al., 1999; Rodriguez et al., 2006; Eden et al., 2003).
Finally, the identification of a wide number of genes with aberrant methylation patterns
in cancer led to the establishment of an enormous amount of methylation biomarkers
for diagnosis, risk prognosis, and prediction of therapy response (Baylin & Jones, 2011;
Witte et al., 2014).
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1.3 Epigenetic and Transcriptional Variability
1.3.1 Introduction to Biological Variability
“Life is a study in contrasts between randomness and determinism”, stated Raj & Van
Oudenaarden (2008). As previously described, genetically identical cells, or organisms,
are able to obtain an incredible variety of phenotypes, even in completely homogenous
environments. Ga¨rtner (1990) showed that, although trying for more than 20 years, it
was not possible to reduce phenotypic variability in animal inbreeding by controlling lab-
oratory settings, and referred to this phenomenon as the “third component”. That is,
neither genetic variability nor the environment could explain the observed phenotypic di-
versity. Since then, many studies suggested that this additional source of diversity arises
from randomness and noise in biological processes such as gene expression (Elowitz et al.,
2002; Raj et al., 2010; Dong et al., 2011; Kaern et al., 2005).
Indeed, biological noise has emerged as an important factor influencing phenotypic vari-
ability. The first experiments measuring variability in the expression of a gene in Es-
cherichia coli via the introduction of two copies of the same promoter into the genome
highlighted the presence of two different causes of fluctuations in gene expression: in-
trinsic noise and extrinsic noise (Elowitz et al., 2002; Swain et al., 2002). The difference
between the two types of noise is illustrated in figure 1.3.
Figure 1.3: Intrinsic and extrinsic noise. Elowitz et al. (2002) constructed Escherichia coli strains by
integrating two reporter genes (shown in green and red respectively) controlled by identical promoters.
Cells with the same amount of protein appear yellow, cells expressing more of one of the two fluorescent
proteins appear in red or green color shades. The expression of the two proteins can become uncorrelated
in individual cells because of intrinsic noise, giving rise to a population in which some cells express more
of one fluorescent protein than the other. When only extrinsic but no intrinsic noise is present, the two
fluorescent proteins fluctuate in a correlated fashion over time, thus, each cell will have the same amount
of both proteins at a given time point.
Figure adapted from Elowitz et al. (2002).
Extrinsic noise are fluctuations that originate from variabilities in external factors such as
the environment (e.g. temperature or pressure), but can also relate to cell-cycle stage, cell
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size, or mitochondrial content, for example. Thus, they affect the expression of all genes
equally in a single cell, but may also be different from cell to cell, or over time (Elowitz
et al., 2002; Raser & O’Shea, 2005; Swain et al., 2002). Extrinsic noise is a fundamen-
tal source of heterogeneity in prokaryotes and eukaryotes (Guantes et al., 2015), and is
probably composed of both stochastic and deterministic influences on the cell (Snijder &
Pelkmans, 2011).
Intrinsic fluctuations in contrast are those that arise due to randomness inherent in bio-
chemical processes in the cell, such as transcription and translation. They are affecting
each copy of a gene independently. Intrinsic stochastic effects become especially promi-
nent when there are only a few molecules of a specific type present in a cell (Elowitz
et al., 2002; Swain et al., 2002).
An important source of intrinsic fluctuations is transcriptional and translational “burst-
ing”. It has been observed that variability in the expression of a gene depends on the
rates of its transcription and translation (Ozbudak et al., 2002). Proteins and also mRNA
molecules are often produced at high frequency in short bursts, which are followed by
quiescent periods, switching the gene randomly on and off for transcription (Raj & Van
Oudenaarden, 2008; Lubeck & Cai, 2012; Raj et al., 2006; Suter et al., 2011). These
bursts have especially been investigated in yeast and mammalian cells, and have been
related to chromatin organization, where transcriptionally silenced heterochromatin leads
to random events of gene activation and inactivation (Raj & Van Oudenaarden, 2008).
1.3.2 Biological Significance and Functions of Variability
Gene expression variability has of course important consequences for cellular function.
Genes that are essential for the functioning of a cell like housekeeping genes which are
responsible for protein synthesis, cell growth and general metabolism, to name a few ex-
amples, require stable and precise expression levels, and indeed, housekeeping genes have
been shown to exhibit less variability than other classes of genes (Raj & Van Oudenaar-
den, 2008; Alemu et al., 2014; Basehoar et al., 2004; Li et al., 2010).
In contrast, genes involved for example in stress-response tend to be highly variable, en-
abling a rapid adaptation of organisms to changing environmental conditions (Blake et al.,
2006; Dong et al., 2011; Kaern et al., 2005; Alemu et al., 2014; Hulse & Cai, 2013), and
thus leading to benefits in survival. This is, because it is easier to achieve large changes
in gene expression in response to signaling if a gene already displays large stochastic
fluctuations in absence of the stimulus, an observation is reminiscent of the “fluctuation
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dissipation theorem”. The theorem states that the response of a variable to perturbation
is proportional to the fluctuation of that variable in absence of an applied force, thus, the
more something varies under normal conditions, the more it will respond to perturbation
(Lehner & Kaneko, 2011). See also figure 1.4 for a demonstration of the concept.
Figure 1.4: Schematic representation of the fluctuation dissipation theorem. The distribution of a
phenotypic trait x1 with large variance (left) shifts more than that of phenotype x2 presenting a smaller
variance (right) in response to a change in parameter a. Thus, the response of each trait is proportional
to its fluctuation.
Figure adapted from Lehner & Kaneko (2011).
It is not only that genes with higher expression variability are more responsive to ex-
ternal stimuli, but there also exists a correlation between expression variation and the
responsiveness to mutation, leading to a faster speed of evolution (Lehner & Kaneko,
2011). Expression variability is subject to evolutionary pressures and therefore linked
with evolvability of complex organisms (Lehner, 2008; Kaern et al., 2005; Hulse & Cai,
2013). So for any particular gene, there exists a relationship between its level of variability,
its responsiveness to perturbation, and the potential to evolve (Lehner & Kaneko, 2011).
This finally leads to a strong correspondence between expression variability due to stochas-
tic processes in single cells from the same population, and expression variability of single
cells across different conditions or time points (Lehner & Kaneko, 2011). The equivalence
between measuring variability at one time point in a population of for example 1,000 ge-
netically identical cells, and measuring the variability of one single cell at 1,000 time
points, is also known as the “ergodic hypothesis”, often practically used to gain informa-
tion about the nature of fluctuations at the single cell level by measuring an ensemble
of cells (Brock et al., 2009). Taking these considerations one step further, it has been
shown that heterogeneity observed within populations correlates with heterogeneity mea-
sured across populations, and – although to a lesser extent – even across species (Lehner
& Kaneko, 2011; Dong et al., 2011; Tirosh et al., 2009; Choi & Kim, 2009; Li et al., 2010).
Besides the mentioned stress-response and signaling, stochastic gene expression is known
to play a key role in development and cellular differentiation in multicellular organisms
(Raj & Van Oudenaarden, 2008; Alemu et al., 2014), by allowing for selection and propa-
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gation of cell type-specific gene expression (Kaern et al., 2005). This has been particularly
investigated in the context of hematopoiesis and the immune system (Enver et al., 1998;
Hume, 2000; Chang et al., 2008).
Immune cells exhibit extensive genetic variation, especially T and B cells. To be able
to respond to a broad range of different antigens, they utilize DNA sequence recombina-
tion to generate diverse cell surface receptors (Satija & Shalek, 2014; Feinerman et al.,
2008). Beside this high variability in their receptor sequences, they also show genetic
and non-genetic variability in further signaling molecules and key transcription factors,
all necessary to generate diverse and effective immune responses (Paszek et al., 2010;
Busslinger & Tarakhovsky, 2014).
Epigenetic diversity plays an important role here (Pujadas & Feinberg, 2012). Epigenetic
modifications have not only been linked to gene expression changes as described previ-
ously in section 1.2, but may also present stochastic fluctuations themselves (Kaern et al.,
2005). This diversity can facilitate fitness-enhancing alterations in changing conditions
(Landau et al., 2014b), as epigenetic states are known to be readily susceptible to envi-
ronmental changes (Richards, 2006), and contributes to the plastic gene expression and
evolutionary landscape in development and differentiation (Pujadas & Feinberg, 2012).
An important additional aspect that has to be taken into account when dealing with gene
expression variability is that variation in gene expression levels does not necessarily affect
the phenotype. This is often referred to as “robustness” (Paszek et al., 2010; Barkai &
Leibler, 1997; Lehner & Kaneko, 2011; Kellogg & Tay, 2015). Furthermore, robustness at
the more global level of biological systems is often achieved through cell to cell coordina-
tion. For example, considering the tight control of programmed cell death in normal cells
it seems unlikely that variation in timing and probability of apoptosis are a consequence
of unstable regulation. Instead, by turning the strict binary decision (apoptosis – yes or
no) at the single cell level into a graded response of the population of cells, variability is
again likely to provide an adaptive advantage (Paszek et al., 2010).
However, gene expression noise can also be undesirable. For example it has been shown
that aging is correlated with an increased level of variability in both gene expression and
also DNA methylation patterns (Raj & Van Oudenaarden, 2008; Li et al., 2010; Fraga
et al., 2005; Southworth et al., 2009; Somel et al., 2006; Bahar et al., 2006; Hannum et al.,
2013). Furthermore, hypervariable gene expression has been linked with human disease
(Alemu et al., 2014; Ho et al., 2008; Prieto et al., 2006; Feinberg et al., 2010).
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While the numbers of both up- and downregulated genes are often similar in classical
differential expression analyses comparing mean levels of expression between disease and
control samples – that is, the number of significant results is similar in both directions of
regulation – it has been shown that gene expression variability instead is predominantly
increased in diseased patients (Ho et al., 2008).
Gene expression variability plays an important role in human immunodeficiency virus
(HIV) susceptibility which is known to greatly vary across individuals (Li et al., 2010),
in neurological disorders (Li et al., 2010; Mar et al., 2011), and it has been strongly
associated with cancer, where it has moreover been recently shown to provide useful and
previously unseen information for diagnostic and predictive purposes (Bravo et al., 2012;
Marusyk et al., 2012).
1.3.3 Variability in Cancer
Traditionally, tumor heterogeneity at different levels – such as intratumoral cell to cell
variability, or heterogeneity across samples or individuals – has been explained by genetic
variability due to random mutations and clonal evolution (Brock et al., 2009; Lengauer
et al., 1998; Gerlinger et al., 2012; Anderson et al., 2011). This view has been challenged
with the development of the cancer stem cell hypothesis, stating that tumorigenesis is
driven by stem cell like cancer cells with indefinite self-renewal potential (Reya et al.,
2001). According to this theory, tumor heterogeneity arises from variable differentia-
tion states of these cells (Marusyk et al., 2012), and not from random genetic mutations
(Brock et al., 2009).
Given that epigenetic modifications are heritable to daughter cells, and therefore subject
to natural selection, the contribution of epigenetic modifications to cancer is probably
substantial, especially because epigenetic alterations accumulate as the cell population
evolves, and diversifies at rates that are orders of magnitude higher than those of somatic
genetic alterations (Landau et al., 2014a). As increased epigenetic heterogeneity results
in a more plastic evolutionary landscape, it facilitates the emergence of both genetic and
epigenetic alterations that enhance fitness (Landau et al., 2014b). Now, it is well known
that epigenetic variability is contributing significantly to tumor heterogeneity (Hansen
et al., 2011; Brock et al., 2009; Landau et al., 2014b; Feinberg & Irizarry, 2010; Issa, 2011).
In all cancers ever investigated in terms of epigenetic variability so far, a strong increase
of variation in tumor samples compared to healthy tissue-matched normal ones has been
observed (Timp & Feinberg, 2013; Pujadas & Feinberg, 2012; Hansen et al., 2011; Jaffe
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et al., 2011), similar to the observations made when looking at gene expression variability
(see above). Additionally, the difference in DNA methylation variability between cancer
and normal samples is strikingly higher than the mean differences in DNA methylation
measured traditionally (Hansen et al., 2011; Pujadas & Feinberg, 2012).
Also in cancer, genes with hypervariable DNA methylation patterns, as well as those
exhibiting increased variability in gene expression, are associated with cellular differenti-
ation, development, mitosis and cell cycle (Pujadas & Feinberg, 2012; Hansen et al., 2011;
Bravo et al., 2012). Furthermore, sites with increased DNA methylation heterogeneity
have been associated to genes that are tissue-specific in normal samples (Pujadas & Fein-
berg, 2012; Hansen et al., 2011), but interestingly not specifically expressed in the normal
tissue of the corresponding cancer (Bravo et al., 2012; Alemu et al., 2014), indicating a
deregulation of particular tissue-specific genes in cancer.
Importantly, stochastic heterogeneity is also linked to therapeutic resistance (Marusyk
et al., 2012). The probably most commonly known example is the one of bacterial re-
sistance after treatment with antibiotics (Balaban et al., 2004). Although most of the
bacterial population is killed by antibiotic treatment, a small subset of so called “per-
sistor” cells can survive, enabling the reemergence of the infection after the treatment
has been stopped (Kaern et al., 2005). Stochastic mechanisms are thought to play a
significant role in these phenomenons (Raj & Van Oudenaarden, 2008).
Similar effects have been observed in cancer cells treated with chemotherapeutic agents
(Brock et al., 2009; Paszek et al., 2010). In fact, many cancer drugs show so called
“fractional killing” (Berenbaum, 1972), in which each round of therapy kills some but
not all cancerous cells (Spencer et al., 2009). Cohen et al. (2008) showed that cell to
cell variability increases after drug addition, with dramatic differences in the dynamics
of the expression of cell death related proteins, allowing some cells to escape from the
treatment. Such effects have also been observed in human cell lines after tumor necrosis
factor related apoptosis-inducing ligand (TRAIL) exposure, where the ability of some
cells to survive apoptosis was linked to noise-driven differences in the levels of proteins
that regulate receptor-mediated cell death.
As such heterogeneity within cancer cell populations leads to relapse with the outgrowth
of resistant cancer cells after initial treatment (Cohen et al., 2008; Gascoigne & Taylor,
2008), and the underlying mechanisms seem often to be non-genetic (Marusyk et al.,
2012), there is a great potential for drugs reducing this diversity via epigenetic modifica-
tions modulating cellular heterogeneity (Sharma et al., 2010; Marusyk et al., 2012; Paszek
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et al., 2010). It is clear that cell to cell variability and changes in cellular phenotypes
resulting from adaptation to treatment and selection for resistant phenotypes need to be
taken into account in order to overcome resistance and improve therapeutic outcome in
cancer treatment (Marusyk et al., 2012).
1.4 Human Blood Cells
Blood contains cells with diverse functions, from the transport of nutrients and oxygen to
the building of antibodies and killing pathogens. All blood cells originate from a pluripo-
tent hematopoietic stem cell, located mainly in the bone marrow, respectively in the liver
in fetuses (Alberts et al., 2004). These stem cells divide infrequently to build new stem
cells (self-renewal) and determined precursor cells that further divide and differentiate
into mature blood cells (Alberts et al., 2004).
The three main components of the blood are red blood cells (erythrocytes), platelets, and
white blood cells (leukocytes), where the leukocytes are further subdivided into myeloid
and lymphoid cells, see figure 1.5.
Figure 1.5: Hematopoiesis. The pluripotent hematopoietic stem cell can replicate and differentiate into
a myeloid or lymphoid stem cell, which can further differentiate into intermediate progenitor cells that
then differentiate into mature blood cells. The myeloid and lymphoid compartment are background
colored in light magenta and cyan.
Figure adapted from OpenStax College (2013).
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Leukocytes are cells of the immune system – described in more detail in my Bachelor
thesis (Ecker, 2009) – responsible for fighting infection and the phagocytosis of foreign
invaders and cell parts.
The most abundant cell type among leukocytes are neutrophils, which belong to the
group of granulocytes. They account for 30 to 80% of all leukocytes (Stemcell Tech-
nologies, 2015) and live only a few hours to days (Alberts et al., 2004; Summers et al.,
2010; Wheater et al., 1979). Neutrophils have a multilobular nucleus and are therefore
also called polymorphonuclear cells. They ingest microorganisms, in particular bacteria,
and are essential in the innate immune system to fight infection. Neutrophils are among
the first responders that migrate to sites of inflammation, and they can release proteins
(granules) to combat infection (Borregaard, 2010). Moreover, they can form so-called
neutrophil extracellular traps (NETs), which are webs of fibers composed of chromatin
and granule proteins that trap and kill pathogens extracellularly (Brinkmann et al., 2004).
The largest leukocytes are monocytes. They live longer than neutrophils, approximately
one to five days (Alberts et al., 2004; Geissmann et al., 2010; Wheater et al., 1979; Pillay
et al., 2010; Kolaczkowska & Kubes, 2013). Monocytes migrate from the blood stream to
other tissues where they mature into macrophages, dendritic cells, and other cell types
(Gordon & Taylor, 2005). Together with neutrophils, they are the phagocytosis experts
of the innate immune system (Hoffbrand et al., 2005), and they constitute 2 to 12% of
all leukocytes (Stemcell Technologies, 2015).
Within lymphocytes, which are mostly found in the lymphatic system where they prolif-
erate, there exist two further important groups of cells, both crucial for the adaptive im-
mune system: B cells, which produce antibodies that can bind to pathogens (“antibody-
mediated immunity”) among other functions, and T cells, which help coordinating the
immune response (“cell-mediated immunity”) and kill virus infected cells (Alberts et al.,
2004). The third group of lymphocytes are natural killer (NK) cells, and as their name
says, they can kill infected and also some cancerous cells.
One of the most abundant T cell types is the naive CD4+ cell, comprising around 1 to 10%
of all leukocytes (Stemcell Technologies, 2015). Naive CD4+ T cells are mature cells that
have not yet encountered their antigen. They are long-lived (living weeks to years), and
their life span increases with age (Tsukamoto et al., 2009). CD4+ T cells are capable
of responding to novel pathogens, get activated when their antigen binds to the T cell
receptor (TCR) and they help antigen-presenting cells through cell to cell interactions
and the secretion of cytokines (Alberts et al., 2004).
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Unstimulated B cells and T cells are morphologically very similar, they are both small
and almost completely filled with their nuclei (Alberts et al., 2004). B cells can be dis-
tinguished from T cells and NK cells by the presence of a different receptor, the B cell
receptor (BCR), allowing a B cell to bind to a specific antigen. B cell development, as
T cell development, occurs through several stages. For T cells this process is described
in my Bachelor thesis (Ecker, 2009).
Each stage of B cell development involves changes in the genome content of the antibody
loci (Janeway et al., 2001). Five classes of antibodies (immunoglobulins) exist in mam-
mals: IgA, IgD, IgE, IgG, and IgM (Alberts et al., 2004). Antibodies are composed of
two identical light (L) and heavy (H) chains. The genes specifying these chains are found
in the variable (V) and constant (C) region (Alberts et al., 2004). In early B cell develop-
ment, every B cell forms a distinct BCR through random combinations in these regions
(Alberts et al., 2004; Zenz et al., 2010). In the heavy-chain V region there are three seg-
ments of recombinations, namely V, D, and J. In the light chain only two segments are
involved in the rearrangement, V and J (Alberts et al., 2004). The random combinations
allow B cells to generate a tremendous diversity of potential BCRs (Janeway et al., 2001;
Alberts et al., 2004; Blachly et al., 2015).
The BCR repertoire is further increased by the process of somatic hypermutation acti-
vated by antigen-binding (Zenz et al., 2010; Alberts et al., 2004). Activated B cells enter
B cell follicles in secondary lymphoid organs, called germinal centers (GCs), where they
undergo massive clonal expansion, accompanied by the process of somatic hypermutation
which modifies the immunoglobulin variable region genes by introducing mutations into
them at a high rate (Klein & Dalla-Favera, 2008; Zenz et al., 2010). Affinity-increasing
mutations are selected, and positively selected B cells normally undergo multiple rounds of
proliferation and mutational selection until they finally differentiate into memory B cells
or plasma B cells and leave the GC (Zenz et al., 2010; Alberts et al., 2004). Many GC
B cells also undergo class-switch recombinations. B cells with unfavorable mutations die
through apoptosis in the GC (Zenz et al., 2010).
1.5 Chronic Lymphocytic Leukemia
1.5.1 The Disease of Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in adults in Western
countries (Rozman & Montserrat, 1995; Caligaris-Cappio & Hamblin, 1999; Zenz et al.,
2010). The disease normally affects elderly people, with a median age of around 72 years
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at diagnosis (Zenz et al., 2010). It rarely occurs in children, and the incidence is higher
in men than in women (Rozman & Montserrat, 1995; Zenz et al., 2010).
In CLL, abnormal B lymphocytes (shown in figure 1.6) which are not able to fight infection
well accumulate in the blood due to the inhibition of cell death (Rozman & Montserrat,
1995; Caligaris-Cappio & Hamblin, 1999). As the number of leukemic cells increases in
the blood and bone marrow, there is less room for healthy leukocytes, red blood cells and
platelets. Over time, the neoplastic cells can spread to other parts of the body, including
lymph nodes, liver, and spleen (Rozman & Montserrat, 1995).
Figure 1.6: CLL cells. High-power magnification (1000 X) of a stained peripheral blood smear. The
lymphocytes with the darkly staining nuclei and scant cytoplasm are CLL cells.
Image taken from Thompson (2006).
The reasons for the development of CLL have not yet been fully elucidated. The disease
is thought to arise due to several pathogenic mechanisms involving microenvironmental
stimuli as well as genetic and epigenetic events (Guarini et al., 2008; Zenz et al., 2010).
Of particular importance in CLL is the BCR, as it is believed that disease onset and
progression is driven by the antigenic stimulation of the BCR and/or cell-autonomous
BCR signaling (Chiorazzi & Ferrarini, 2003; Quiroga et al., 2009; Iacovelli et al., 2015).
CLL cells exhibit stereotyped BCRs across patients (Du¨hren-von Minden et al., 2012),
supporting the hypothesis that the recognition of specific antigens drives CLL pathogen-
esis and evolution of the disease (Zenz et al., 2010; Herishanu et al., 2011; Du¨hren-von
Minden et al., 2012). Consequently, as signaling by antigens and the BCR can influence
the clinical course of CLL, it has been suggested as a therapeutic target (Herishanu et al.,
2011), and the inhibition of BCR signaling seems to be a promising approach in early
clinical trials indeed (Friedberg et al., 2010; Shain & Tao, 2013).
However, the diagnosis of CLL does not directly imply the need for therapy, as it does
usually not cause symptoms at early stages and is often only found during routine blood
tests returning abnormally high white blood cell counts (Rozman & Montserrat, 1995;
Zenz et al., 2010). Such patients in early stages of the disease get monitored closely, but
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only problems caused by the disease, such as infection, are treated, and not the leukemia
itself. Treatment of CLL gets started when the disease has progressed to a point where
it may affect the patient’s quality of life, when constitutional symptoms such as bulky
lymphadenopathy or splenomegaly appear, and when specific markers according to clin-
ical staging systems are met (Rozman & Montserrat, 1995). The current gold standard
in patient evaluation and treatment decision in CLL are the staging systems of Rai et al.
(Rai et al., 1975; Rai & Han, 1990) and Binet et al. (1981).
Although CLL is considered incurable, later stages of the disease can be treated by differ-
ent options including radiation therapy, chemotherapy, surgery (removal of the spleen),
stem cell transplantation, and monoclonal antibody therapy (also called biotherapy) given
by infusion (Rozman & Montserrat, 1995).
However, CLL generally progresses slowly in most cases. Due to the often indolent course,
older patients with early and stable disease may not need any treatment in their lifetimes
and survive as long as normal subjects of the same age (Rozman & Montserrat, 1995).
Early therapeutic intervention does not improve survival time or quality of life of the pa-
tients (French Cooperative Group on Chronic Lymphocytic Leukemia, 1990; Montserrat
et al., 1991; Catovsky et al., 1991; CLL Trialists’ Collaborative Group, 1999) and has
even been associated with shorter survival (Montserrat et al., 1991).
The prognosis of CLL is however highly variable, and there exist subtypes of CLL with
very different clinical outcomes. Important prognostic parameters are for example the ex-
pression of the intracellular protein ZAP70 (zeta-chain-associated protein kinase 70) and
the membrane glycoprotein CD38 (cluster of differentiation 38). CLL that is positive for
these markers shows decreased average survival (Zent & Kay, 2007; Rassenti et al., 2008).
Additionally, CLL prognosis is dependent on genetic changes within the neoplastic cell
population. The major genetic aberrations impacting clinical outcome in CLL are the
following (Do¨hner et al., 2000; Rozman & Montserrat, 1995):
• Deletions of chromosome 17 which target the cell cycle regulation protein P53 (tu-
mor protein 53). Patients with this abnormality have a significantly shorter time
to treatment and show often poor response to conventional drug therapy (Fabris
et al., 2008). The deletion is found in 5–10% of the patients.
• Deletions on chromosome 11 that target the ATM (ataxia telangiectasia mutated)
gene. The deletion is unfavorable and affects 5–10% of the patients.
• An additional chromosome 12. It is found in 20–25% of the patients and leads to
an intermediate prognosis (Juliusson & Gahrton, 1993; Gahrton et al., 1980).
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• Deletion at band q14 of chromosome 13 is the most common one in CLL. The
region targets the RB1 (retinoblastoma 1) gene (Rozman & Montserrat, 1995; Fa¨lt
et al., 2005) and a microRNA cluster (Mraz et al., 2009) that functions as a tumor
suppressor, with oncogene BCL2 (B cell CLL/lymphoma 2) as its target (Bonci
et al., 2008). Patients with this deletion have a more favorable prognosis. About
50% of patients have this defect in their CLL cells.
• Deletions of chromosome 6 and 11 (Juliusson & Gahrton, 1993).
The most reliable and best-studied diagnostic parameter in CLL is the mutation status of
the immunoglobulin sequence (Zent & Kay, 2007), leading to two subgroups of patients
with different clinical courses (Hamblin et al., 1999; Zenz et al., 2010; Damle et al., 1999;
Chiorazzi & Ferrarini, 2003).
The immunoglobulin variable-region heavy chain (IgVH) gene mutation status reflects
the maturity of the lymphocytes, as the IgVH somatic hypermutation is a physiologic
marker of antigen exposure and passage through the germinal center (Zent & Kay, 2007;
Rosenwald et al., 2001), see also section 1.4. Increased somatic mutation rates in the
corresponding region – that is 2% or greater difference from the germline sequence –
indicate mature lymphocytes, and CLL patients showing IgVH gene mutations have a
significantly better prognosis (Hamblin et al., 1999), presenting a median survival of
more than 24 years (Chiorazzi & Ferrarini, 2003). This subtype of CLL is referred to as
IgVH “mutated” CLL (M-CLL). In contrast, IgVH “umutated” CLL (U-CLL) shows a
more immature cell pattern with few mutations in the IgVH antibody gene region (Ham-
blin et al., 1999) and U-CLL patients are high risk patients with worse prognosis and a
median survival of 4–8 years (Chiorazzi & Ferrarini, 2003).
U-CLL patients are at average slightly older at diagnosis than patients with M-CLL
(Hamblin et al., 1999). The two groups M-CLL and U-CLL also show several further
biological differences with implications for clinical outcome: different levels of ZAP70
and CD38 expression, differential activity of key signal transduction pathways, differ-
ent telomere lengths, different proliferation capacity, and different likelihood of genetic
lesions and mutations (Kro¨ber et al., 2002; Klein et al., 2001; Rosenwald et al., 2001; Stil-
genbauer et al., 2007; Puente et al., 2011). In summary, U-CLL cells are more likely to
show alterations associated to poor prognosis, whereas M-CLL shows higher proportions
of changes with favorable clinical outcome (Chiorazzi & Ferrarini, 2003).
Further information about CLL, especially gene expression and DNA methylation in CLL
and its subtypes, can be found in Annex 2.
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1.5.2 Variability in Chronic Lymphocytic Leukemia
Tumor heterogeneity has been traditionally investigated in solid malignancies, with an
emphasis on analyzing genetic variation and clonal evolution, as described in section 1.3.3.
However, even CLL, previously thought to progress via monoclonal expansion (Rozman
& Montserrat, 1995; Klein et al., 2001) can display genetic variability, both at the level
of single tumoral cells as well as through clonal heterogeneity (Stilgenbauer et al., 2007;
Landau et al., 2013; Gurrieri et al., 2002; Quesada et al., 2011; Wang et al., 2011; Schuh
et al., 2012; Landau et al., 2014a; Gunnarsson et al., 2011).
Increased genomic complexity has been correlated with decreased survival in CLL (Roos
et al., 2008; Ramsay et al., 2013), and interestingly, clonal evolution seems to occur
mainly in U-CLL cases (Stilgenbauer et al., 2007; Herishanu et al., 2011; Landau et al.,
2014a; Gunnarsson et al., 2011) while M-CLL shows an increased number of (clonal, but
not subclonal) somatic mutations compared to U-CLL (Landau et al., 2013; Puente et al.,
2011; Quesada et al., 2011).
As stated in section 1.3.3, genetic variability might have an impact on epigenetic and
transcriptional variability and vice versa, and also in CLL epigenetic modifications are
probably involved in the phenotypic differences observed. Indeed, when Landau et al.
(2014b) analyzed DNA methylation data of CLL, they found higher intra-sample het-
erogeneity in the leukemia cases compared to normal B cell samples, resulting from an
increased proportion of cells with variable methylation patterns in terms of discordant
methylation states in neighboring CpGs, called “locally disordered methylation”.
This disordered methylation appeared to arise from stochastic processes, and was sig-
nificantly associated with a reduced correlation between promoter methylation and gene
silencing. Additionally, Landau et al. (2014b) found higher levels of disordered methy-
lation in promoters of genes that showed already increased methylation variability in
normal B cells, and in promoters of genes that were transcriptionally silenced in both
normal B cells and CLL.
The genes affected by locally discordant methylation were enriched for genes impor-
tant to pluripotency potential such as stem cell modules. Samples with increased DNA
methylation heterogeneity also exhibited higher numbers of subclonal mutations. Finally,
increased heterogeneity at the level of DNA methylation was associated with shorter sur-
vival in the study of Landau et al. (2014b).
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Oakes et al. (2014) reported in another publication that DNA methylation heterogeneity
correlated with advanced genetic subclonal complexity, and that it occurred at higher
levels in U-CLL cases, again suggesting that DNA methylation variability might be as-
sociated with a more aggressive disease.
Also in CLL, tumor heterogeneity is a crucial factor to consider in therapy, as treatment
often seems to accelerate evolution from heterogeneity present before the start of the ther-
apy to increased fitness and a more aggressive phenotype of the disease (Landau et al.,
2013). This is thought to occur by favoring the rapid growth of more aggressive clones
which benefit from the removal of incumbent clones due to the treatment, supporting
the view that not treating CLL in early indolent stages (see section 1.5) leads to better
clinical results (Landau et al., 2014a).
Finally, it has been concluded that diversity at any level, be it genetic or non-genetic,
is sufficient to influence clinical outcome in CLL, and monitoring heterogeneity during
disease course might be a beneficial strategy to improve therapeutic decisions and risk
prediction in patients (Kleppe & Levine, 2014; Swanton & Beck, 2014; Oakes et al., 2014;
Landau et al., 2013).
Variability at the level of gene expression has however not been investigated in CLL
so far.
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Chapter 2
Objectives
The aim of this work is to characterize interindividual epigenetic and transcriptional
variability and their interrelationship in the human hematopoeitic system in both health
and disease, with a special emphasis on the following two areas that are investigated in
detail in this context:
• Chronic lymphocytic leukemia
• Normal blood cells
Within these two main areas of the present thesis, the specific aims for each of them are
the following:
1. Analysis of Variability in Chronic Lymphocytic Leukemia
• Measuring differential gene expression variability between the two main CLL sub-
types using robust methods to quantify variability taking the mean-variance rela-
tionship into account.
• Validating the findings on differential variability in independent publicly available
CLL datasets.
• Analyzing the relation between gene expression variability and DNA methylation
in CLL.
• Characterizing the functions of genes with differential expression variability.
• Predicting the disease subtype of patients based on expression variability measure-
ments.
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2. Analysis of Variability in Normal Blood Cells
• Establishing robust and comparable methods to quantify interindividual variability
as well as mean differences in both DNA methylation and gene expression data able
to deal with the complex relationship between mean and variability measurements.
• Analyzing differential DNA methylation variability across monocytes, neutrophils
and T cells.
– Identifying cell type specific sites with hypervariable DNA methylation patterns.
– Identifying sites with hypervariable DNA methylation patterns shared between
two of the three cell types.
– Identifying sites with hypervariable DNA methylation patterns in common in
all three cell types.
• Analyzing differential gene expression variability across monocytes, neutrophils and
T cells.
– Identifying cell type specific genes with hypervariable gene expression patterns.
– Identifying genes with hypervariable gene expression patterns shared between
two of the three cell types.
– Identifying genes with hypervariable gene expression patterns in common in
all three cell types.
• Analyzing sex-specific differential DNA methylation and gene expression within
each cell type and its possible contribution to interindividual variability.
• Analyzing the relation between DNA methylation variability and gene expression.
Thus, the main focus of this writing lies on the analysis of differential variability, with a
comprehensive analysis of differential gene expression variability between the two main
subtypes of CLL, and the creation of robust methodology to analyze both differential
DNA methylation variability and gene expression variability, applied on a dataset com-
prising three normal blood cell types – monocytes, neutrophils and T cells.
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Chapter 3
Methods
3.1 Gene Expression Variability in CLL
The description of materials and methods given in this section is also published in a
modified form in Ecker et al. (2015).
3.1.1 Material
The work on gene expression variability in CLL presented here was conducted within the
framework of the ICGC (International Cancer Genome Consortium, 2010). The ICGC
coordinates large-scale cancer genome studies of 50 different tumor types and subtypes
of clinical and societal importance around the globe. The aim of the consortium is to
obtain a comprehensive catalogue of genomic, transcriptomic and epigenomic alterations
in these cancer types. Our group participates in the Spanish Consortium with its CLL
Genome Project (International Cancer Genome Consortium, 2015), which aims to de-
cipher the diversity and complexity of genomic, epigenomic and transcriptomic changes
in the genome of CLL and its subtypes M-CLL and U-CLL with the ultimate goal to
improve prevention, diagnosis and treatment of the disease.
The first publications of the ICGC CLL Genome Project described recurrent mutations
in CLL (Quesada et al., 2011; Puente et al., 2011). Subsequent studies focussed on
the DNA methylome (Kulis et al., 2012) and transcriptome (Ferreira et al., 2014) of
the disease and its subtypes, and gave rise to the here presented work. The preceding
epigenomic and transcriptomic studies of CLL in which we also participated are summa-
rized in Annex II where the corresponding papers we have published can be found as well.
For the study of gene expression variability in CLL presented in this thesis we used the
ICGC CLL microarray datasets previously described in Kulis et al. (2012) and Ferreira
et al. (2014), together with additional publicly available datasets for validation.
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Gene expression measurements of the ICGC data were obtained by Affymetrix Human
Genome U219 Array Plates by Kulis et al. (2012) and Ferreira et al. (2014). A total of
48,786 features of the microarray passed quality controls and filtering. Raw files were
preprocessed and normalized by Kulis et al. (2012) and Ferreira et al. (2014) using the
robust multi-array average (RMA) algorithm (Irizarry et al., 2003) and the Affy package
(Gautier et al., 2004). The dataset comprises 122 CLL samples (70 M-CLL and 52 U-
CLL) and 20 control samples of different healthy B cells (five naive B cells, three IgM+
and IgD+ memory B cells, four IgA+ and IgG+ memory B cells, and eight CD19+ Bcells).
For the validation of our results, we included an additional gene expression dataset of
CLL published by Fabris et al. (2008) under gene expression omnibus (GEO) accession
number GSE9992, containing 60 samples (24 M-CLL and 36 U-CLL) and 22,215 probes
in our analyses. The microarray platform used in this study was the Affymetrix Human
Genome U133A Array. The data were quality assessed and preprocessed independently
from the ICGC gene expression dataset. For normalization we used the fRMA algorithm
(McCall & Irizarry, 2011).
To further confirm the main results of our analysis we used data published by Haslinger
et al. (2004). This dataset is available under GEO accession number GSE2466 and we
analyzed the 39 samples of M-CLL and the 33 U-CLL samples which were hybridized
onto the Affymetrix Human Genome U95 Version 2 Array containing 12,625 probes. The
dataset was normalized using the RMA algorithm (Irizarry et al., 2003).
DNA methylation was measured by Infinium Human Methylation450K BeadChips. A to-
tal of 282,470 probes (139,076 of them falling into gene promoter regions) passed quality
control and filtering procedures of Kulis et al. (2012). The data were analyzed by Genome
Studio (Illumina, Inc.) and R using the lumi package (Du et al., 2008), and an optimized
analysis pipeline was developed and applied by Kulis et al. (2012). This pipeline includes
several filters to exclude technical and biological biases that might produce false results,
removing probes with low detection p-values, sex-specific and individual-specific methy-
lation, or overlapping with single nucleotide polymorphisms (SNPs). To correct for the
differing performance of Infinium I and Infinium II assays, subset-quantile within array
normalization (SWAN) was applied (Makismovic et al., 2012).
3.1.2 Measuring Gene Expression Variability
We used two different measures to quantify gene-wise expression variability. Firstly, we
calculated the coefficient of variation (CV) of every gene i, defined as the ratio between
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the sample standard deviation si of expression values across patients and the sample
mean x¯i, see formula 3.1.
CVi =
si
x¯i
(3.1)
Secondly, we quantified expression variability using the expression variability score intro-
duced by Alemu et al. (2014), subsequently called EV. Alemu et al. (2014) applied local
polynomial likelihood estimation Loader (1999) to model variance as a function of the
mean of expression. In some more detail, the method assumes that variance is gamma
distributed and estimates the expected variability of a gene given its overall expression
values by a gamma regression model using a locally weighted quadratic polynomial. The
ratio of observed variance to expected variance gives then the measurement of expression
variability for each gene.
To compare gene expression variability between M-CLL and U-CLL and identify the
top genes with differential variability, we calculated gene-wise CV differences CVdiffi =
CVi,M-CLL − CVi,U-CLL and EV differences EVdiffi = EVi,M-CLL − EVi,U-CLL.
To assess statistical significance, we performed gene-wise F-tests (Snedecor & Cochran,
1989) comparing M-CLL with U-CLL using R’s var.test() function (R Development
Core Team, 2008). Multiple hypotheses testing correction was performed using the
Benjamini-Hochberg algorithm (Benjamini & Hochberg, 1995).
3.1.3 Analysis of DNA Methylation and its Relationship to
Gene Expression Variability
To investigate the relationship between gene expression and DNA methylation, we mapped
the microarray probe identifiers to Ensembl identifiers and used the average of the mea-
surements for each gene. DNA methylation features were mapped to genomic regions
using annotation information provided by Illumina, see Kulis et al. (2012). We applied
the bumphunter method (Jaffe et al., 2011) to identify regions of differential methylation
between M-CLL and U-CLL. Smoothing of methylation values was applied and 1,000
permutations were performed to assess statistical significance.
Subsequently, we looked at the genomic annotation of the microarray probes within the
regions which had been identified to be differentially methylated and assigned all regions
to be either promoter regions or gene body regions if they contained at least three probes
of the corresponding annotation. Regions not containing the described minimum of three
probes were excluded from further analyses.
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To detect if genes with their promoters or gene bodies lying within differentially methy-
lated regions were significantly enriched in genes with increased variability in U-CLL we
performed hypergeometric tests for both hyper- and hypomethylated regions using the R
function phyper(). The test was performed on the basis of the 15,037 genes in common
between the DNA methylation and gene expression data we used.
3.1.4 Functional Analysis
To test for enrichment of biological functions and pathways we used DAVID (Huang
et al., 2009). We uploaded the list of the top 500 genes of the ICGC CLL dataset and
the top 500 genes of the Fabris CLL dataset and used the corresponding set of genes ana-
lyzed in the dataset as background set. We tested for the following functional annotation:
GOTERM BP ALL, GOTERM CC ALL, GOTERM MF ALL, KEGG PATHWAY, and
REACTOME PATHWAY and set the threshold of counts to a minimum of three genes.
We considered terms and pathways as significantly enriched when the corresponding
p-value adjusted by the Benjamini-Hochberg algorithm for multiple hypotheses correc-
tion (Benjamini & Hochberg, 1995) was smaller than 0.05.
The same analyses were performed in R using the packages GOstats (Falcon & Gen-
tleman, 2007) and Category (Gentleman, 2015), and very similar results were obtained
(data not shown).
The enrichment analyses on the five network modules were performed the same way as
described above, except the background gene set used, which in this case was the set of
all genes contained in the entire B cell network of Lefebvre et al. (2010) that are also
present on the microarray platforms investigated (n = 5,548).
3.1.5 Random Forest Classification
We applied the randomForest R package (Liaw & Wiener, 2002) to create random forest
classifiers and the package ROCR (Sing et al., 2005) to calculate area under the curve
(AUC) values, which were used to evaluate the prediction of the disease subtype of the
patients in our independent validation dataset.
3.1.6 Programming Language
If not stated otherwise, the analyses were performed using R version 3 (R Development
Core Team, 2008) and Bioconductor (Bioconductor, 2015).
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3.2 Variability in Normal Blood Cells
3.2.1 Material
We analyzed the DNA methylation microarray and RNA sequencing (RNAseq) pilot
dataset generated by BLUEPRINT (Adams et al., 2012) for its Human Variation Epigenome
Project (see figure 3.1). The BLUEPRINT epigenome project is a large-scale European
research effort in which our group participates. It is the European cornerstone of the
International Human Epigenome Consortium (IHEC), an international research coopera-
tion aiming to coordinate epigenome mapping for a broad spectrum of human cell types.
Figure 3.1: Overview of the dataset comprising the transcriptome and DNA methylome of monocytes,
neutrophils and T cells derived from 48 individuals. In the future, the dataset will be extended to
200 individuals. Furthermore, histone marks will be added, and whole genome sequencing (WGS) data
obtained from whole blood will also be available for all individuals. The colors of the three cell types
represent the color scheme used in all subsequent figures comparing these cell types.
Images of cell types adapted from Blausen.com (2014).
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The aim of the BLUEPRINT consortium is to generate at least 100 reference epigenomes
of distinct types of human hematopoietic cells from healthy individuals and their malig-
nant leukemic counterparts to advance the knowledge of biological processes and mecha-
nisms in health and disease, systematically linking epigenetic variation with phenotypic
plasticity in both health and disease.
The BLUEPRINT dataset used in this work comprises DNA methylation and gene ex-
pression data of three different blood cell types: monocytes, neutrophils and T cells (see
section 1.4 for an introduction of these cell types). The samples were derived from 48
unrelated healthy individuals. An overview of the data can be found in figure 3.1. Al-
together, the dataset contains samples derived from 34 male and 14 female individuals
within an age range of 30 to 70 years. Data of T cells are only available for 40 of the 48
individuals.
In the future, the dataset will be extended to 200 individuals, and several histone
marks will be added: H3K4me1 and H3K27ac for all three cell types, and additionally
H3K27me3 for neutrophils. Also WGS data obtained from whole blood will be available
for all individuals contained in the study.
3.2.2 Data Preprocessing and Filtering
The general preprocessing, quality assessment and filtering of the DNA methylation and
gene expression data was done by others at University College London Cancer Institute
and Wellcome Trust Sanger Institute respectively, and is therefore only summarized here
for completeness.
DNA methylation measurements were obtained by Infinium Human Methylation450K
BeadChips. Raw data (IDAT files) containing information for all 485,512 probes were
normalized using minfi (Aryee et al., 2014) and functional normalization (Fortin et al.,
2014), and batch-effect corrected by ComBat (Johnson et al., 2007). Probes were filtered
corresponding to the following criteria:
• probes with median detection p-value > 0.01 in more than one sample
• probes with bead count of less than three in more than 5% of samples
• probes mapping to sex chromosomes
• probes mapping to multiple locations with at least two mismatches
• non-CG probes
• probes with SNPs in European population based on 1000 Genomes Project phase I
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A set of 423,089 probes passed the filtering procedure. Seven of the 40 DNA methylation
samples of T cells were excluded from the analyses because of quality problems.
RNAseq data (100 bp single-end, total RNA) was quality controlled using FASTQC
(Andrews, 2014). Sequencing reads were aligned to the GRCh37 human reference genome
using STAR (Dobin et al., 2013) and GSNAP (Wu & Nacu, 2010). Reads not uniquely
mapping to the genome were removed, permitting default mismatches. Expression read
counts of 62,069 ensembl genes were obtained by MMseq (Turro et al., 2011).
3.2.3 Measuring DNA Methylation and Gene Expression
DNA methylation can be quantified by Beta-values (see formula 3.2) or M-values (see
formula 3.3), where the Beta-value is the ratio of the methylated probe intensity and the
overall intensity, and the M-value is the log2 ratio of the intensities of the methylated
probe versus the unmethylated probe.
Betai =
max(yi,methyl, 0)
max(yi,unmethyl, 0) +max(yi,methyl, 0) + α
(3.2)
Mi = log2
(
max(yi,methyl, 0) + α
max(yi,unmethyl, 0) + α
)
(3.3)
yi,methyl and yi,unmethyl are the intensities measured by the i
th methylated and unmethy-
lated probe. The offset α is added to the denominator to regularize the value when both
methylated and unmethylated intensities are low. The distribution of both Beta-values
and M-values in our data can be seen in supplementary figure SF7 in Annex I.
The Beta-value results in a number between zero and one, which can also be interpreted
as a percentage (0 or 100%). A value of one stands for complete methylation, a value of
zero means that none of the measured molecules was methylated.
The M-value as a log ratio can be positive (more methylated) and negative (more un-
methylated), where a value of zero represents intermediate methylation with half of the
measured molecules methylated, and half of them unmethylated.
Beta-values can be transformed into M-values using formula 3.4 (Du et al., 2010):
Betai =
2Mi
2Mi + 1
;Mi = log2
(
Betai
1−Betai
)
(3.4)
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This conversion ignores the offset α of formula 3.2 and 3.3, which has been shown to only
have negligible effects for the majority of probes (Du et al., 2010).
We performed all analyses on M-values, except the part of the comparison of methods for
measuring differential variability in DNA methylation data, where also the performance
of Beta-values compared to M-values was investigated. Due to its easier interpretability
as percentage of methylation however, we used the Beta-value when visualizing methyla-
tion values of genes exhibiting differential DNA methylation variability.
For the analysis of gene expression data, RNAseq counts (see section 3.2.2) were converted
into expression log counts using R’s function log1p(x).
3.2.4 Analysis of DNA Methylation Variability
All the 423,089 probes that passed quality control and filtering procedures as described
in section 3.2.2 were used in the analysis of DNA methylation variability.
For the comparison of different methods to measure differential variability we used the
following R functions and packages:
• Bartlett’s test (Bartlett, 1937) implemented in R’s function bartlett.test()
• The Ansari-Bradley test (Ansari & Bradley, 1960) implemented in R’s function
ansari.test()
• Haim Bar’s mixture model (Bar et al., 2012) with code provided via personal com-
munication (available at code haim bar.html) and calling the harvest() function
• DiffVar of the missMethyl package version 1.2.0 (Phipson & Oshlack, 2014) available
from Bioconductor (2015)
Statistical significance was defined by Benjamini-Hochberg corrected p-values (Benjamini
& Hochberg, 1995) smaller than 0.05.
The genomic annotation of the probes was made based on Illumina’s manifest for the
450K BeadChip microarray (Illumina Inc, 2015). We defined “TSS200”, “TSS1500”,
“5’UTR” and “1stExon” as belonging to gene promoters, and “Body” and “3’UTR” as
belonging to gene bodies.
3.2.5 Analysis of Gene Expression Variability
For the analysis of gene expression variability, first of all we normalized the RNAseq
dataset by library size using DESeq2 (Love et al., 2014). Then we removed all genes with
34
CHAPTER 3. METHODS
no reads in more than 50% of the samples in one or more of the groups in order to only
work with genes that are expressed in all three cell types. Furthermore, we included only
protein coding genes. This led to a total number of 12,661 ensembl genes included in the
analysis.
To measure differential expression variability with DiffVar (Phipson & Oshlack, 2014),
the recommendation of its vignette was followed. In short, the count matrix was con-
verted into a DGEList (Robinson et al., 2009), a scaling normalization (Robinson et al.,
2009) was performed using the function calcNormFactors(), and a voom normalization
was applied (Law et al., 2014; Ritchie et al., 2015; Phipson & Oshlack, 2014).
Statistical significance was defined by Benjamini-Hochberg corrected p-values (Benjamini
& Hochberg, 1995) smaller than 0.05.
3.2.6 Analysis of Sex-Specific Differential Expression and DNA
Methylation
Also for the analysis of gender differences within each cell type, the RNAseq data normal-
ized by library size (see preceding section 3.2.5) was used. All genes without reads in more
than 90% of the samples were removed, leading to a set of 38,824 genes. Genes of the sex
chromosomes were maintained in the dataset to serve as a positive control, but excluded
from any results reported. A scaling normalization (Robinson et al., 2009) as well as voom
normalization (Law et al., 2014; Ritchie et al., 2015) was performed before conducting
the analysis of differential expression by limma (Smyth, 2005; Ritchie et al., 2015). Genes
were considered as significantly differentially expressed when their Benjamini-Hochberg
corrected p-values (Benjamini & Hochberg, 1995) were smaller than 0.05.
Hypergeometric tests to assess whether overlaps between genes with increased gene ex-
pression variability and genes with sex-specific differential expression were bigger than
expected by chance were performed using R’s function phyer() on the basis of the 12,661
genes included in the analyses of differential variability.
Functional enrichment analyses of genes differentially expressed between males and fe-
males were performed with DAVID (Huang et al., 2009) testing for GOTERM BP ALL,
GOTERM CC ALL, GOTERM MF ALL. The same analysis was repeated using the
R package GOseq (Young et al., 2010). For both analyses the threshold of counts was
set to a minimum of three genes and we considered terms as significantly enriched when
the corresponding Benjamini-Hochberg adjusted p-values (Benjamini & Hochberg, 1995)
were smaller than 0.05.
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For the analysis of gender-specific differential methylation within each cell type we used
the same limma model as for the analysis of sex-specific differential expression. No
additional filtering was applied on the matrix of methylation M-values before performing
the statistical analysis.
3.2.7 Programming Language
If not stated otherwise, the analyses were performed using R version 3 (R Development
Core Team, 2008) and Bioconductor (Bioconductor, 2015).
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Chapter 4
Results & Discussion
4.1 Gene Expression Variability in CLL
4.1.1 Overview
The focus of this work lies on the investigation of gene expression variability across in-
dividuals, an important parameter to be measured alongside the average levels of gene
expression.
While studies on differences in mean levels of different human traits abound, few studies
focused on variability so far, in part because of the larger numbers of observations nec-
essary to accurately estimate variability which have only recently become available, and
on the other hand because the importance of the information present in the distributions
of biological data has often been overlooked so far. The gain of information from an im-
proved understanding of phenotypic heterogeneity has only started to be appreciated in
recent years (Ho et al., 2008; Alemu et al., 2014; Paszek et al., 2010; Feinberg & Irizarry,
2010; Hansen et al., 2011), as described in more detail in section 1.3. For CLL, there is
increasing evidence that genetic and epigenetic heterogeneity are a crucial characteristic
of disease development and progression (see section 1.5.2), but if and to which extent
such heterogeneity is also present at the level of gene expression in CLL has not been
previously investigated.
Here, we demonstrate that the two major clinical subtypes of CLL, M-CLL and U-CLL,
which have very similar mean expression levels with only a small number of differentially
expressed genes between the two subtypes (see also Ferreira et al. (2014) and Annex
2), show strong differences in gene expression variability, suggesting an impact of gene
expression heterogeneity on tumor adaptability and aggressiveness in CLL.
The main results described in the following sections have also been published in Ecker
et al. (2015).
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4.1.2 Measuring Gene Expression Variability
In contrast to traditional analyses of differences in mean of any measured trait, here, we
aimed to find genes with differential variability between groups, i.e. increased variability
in one group compared to the other, as illustrated in figure 4.1, which shows the concept
using synthetic data.
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Figure 4.1: Differential variability versus differential mean in synthetic data. Data points represent
individual measurements. These measurements could for example be gene expression values of a certain
gene in all individuals within the group. In this case, every data point would represent the expression
value of a gene in one individual, with multiple points representing different individuals of which the
measurement of the same gene was obtained. Boxplots display the summary distribution of the underlying
data points.
However, in real data, the two are not always as clearly separated from each other as
in figure 4.1, and a gene can exhibit both, a significant difference in mean, but also in
variability. It is important to take into account that there exists a dependence of expres-
sion variability on mean expression levels, making it sometimes hard to tear the effect
of mean expression apart from variability measurements. Thus, we employed different
measures of gene expression variability in order to obtain robust estimates of expression
heterogeneity, and to avoid obtaining results of differential variability that are merely
driven by differences in mean.
For the start, we studied gene expression variability in the ICGC dataset using the coef-
ficient of variation (CV). The CV is defined as the ratio between the standard deviation
(SD) of the variable measured across the patients and its mean (see section 3.1.2 and
formula 3.1). As gene expression variability in terms of the CV is dependent on mean
expression levels, we analyzed the dependence of the CV on the level of expression of the
corresponding genes, see figure 4.2.
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Figure 4.2: Definition of the CV and its dependence on gene expression levels. Left panel: CV versus
expression of genes in bins of increasing expression level. Middle panel: Relationship between reciprocal
of mean expression and expression in bins of increasing expression level. Right panel: Dependence of the
standard deviation of expression across patients on the level of expression. The widths of the boxplots
are relative to the number of genes contained in each gene expression bin (see also table 4.1).
Figure taken from Ecker et al. (2015).
The numbers of the genes contained in the bins shown in figure 4.2 are given in table
4.1. The relationship between the CV and mean expression levels is interesting and non-
trivial. The highest levels of expression variability are observed for genes with low to
intermediate levels of expression, and not for genes expressed at high or extremely low
levels.
Table 4.1: Gene expression bins. The second column shows the expression values within every single
bin and the last column lists how many genes are contained in the corresponding bin, also indicated by
relative box widths in figure 4.2.
Bin Gene expression values Nr of genes
1 < 4.5 9,101
2 ≤ 4.5 and < 5.5 3,355
3 ≤ 5.5 and < 6.5 2,402
4 ≤ 6.5 and < 7.5 1,987
5 ≤ 7.5 and < 8.5 1,517
6 ≤ 8.5 and < 9.5 986
7 ≤ 9.5 and < 10.5 435
8 ≤ 10.5 and < 11.5 224
9 ≤ 11.5 and < 12.5 74
10 ≤ 12.5 68
To understand the origin of this behavior it is important to take the intrinsic stochasticity
of biological processes into account. The impact of fluctuations is inversely proportional
to the number of elements involved in a system. This is a well-established phenomenon
observed in physical systems (Kampen, 2007), and well characterized in biology (Kaern
et al., 2005; Lehner & Kaneko, 2011). Indeed, there is component of the CV that is given
by the inverse of the mean of expression, as an 1/x dependence (see figure 4.2). This
dependence reflects the fact that introducing an additional element in a small number
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of observed traits – here, an extra copy of RNA of a lowly expressed gene – will have
more dramatic consequences than an additional one in a huge amount of elements – here
corresponding to an extra copy of a gene that is expressed in high numbers (see also
figure 1.1). The latter will not produce a substantial change.
Certainly, stochastic processes of this kind are not likely to be the only determinants of ex-
pression variability. The remaining component of the CV is the SD, which has a negative
quadratic dependence on the mean of expression (see figure 4.2), showing higher values
for intermediate expression levels. Concluding, these observations highlight the impor-
tance of taking gene expression levels into account when evaluating expression variability.
Although the CV is known to be one of the most robust and unbiased metrics to quantify
expression variability (Li et al., 2010; Kaern et al., 2005) and is the current gold-standard
measurement, we employ an additional measure of expression variability which has re-
cently been proposed by Alemu et al. (2014), subsequently called EV. The EV tries to
account for the above described relationship between mean expression levels and variabil-
ity in a distinct way and provides a measure of variability which is independent of the
expression mean. It models variance as a function of the mean and gives the quantifica-
tion of expression variability as the ratio of observed variance to expected variance for
each gene (see section 3.1.2 and supplementary figure SF1 in Annex I for details on the
method).
Despite the above described biological relevance of the relationship between mean ex-
pression levels and expression variability, introducing such a measure which “corrects”
for the dependence of variability on mean expression levels has the advantage of being
able to tear apart the effect of differing mean expression levels from variability estima-
tions. Otherwise, increased expression variability observations in a gene could only be
caused by differing mean expression levels.
We observed a high correlation between the CV and EV in the datasets we analyzed,
with a Pearson correlation coefficient of 0.74 (p < 2.2× 10−16) in the ICGC data and of
0.87 (p < 2.2× 10−16) in the dataset of Fabris used for validation (the correlation can
also be seen supplementary figure SF2 in Annex I). In all subsequent analyses we took
both measures of gene expression variability into account.
4.1.3 Gene Expression Variability in the Two Subtypes of CLL
Next, we investigated whether gene expression variability differs between M-CLL and
U-CLL, and could therefore be behind the different aggressiveness the two clinical dis-
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ease subtypes. We plotted both the genes’ CV and EV of M-CLL versus the CV and
EV of U-CLL respectively, and consistent with our hypothesis gene expression variability
shows a clear difference between the two subtypes, with higher variability associated to
U-CLL, the more aggressive subtype of the disease (see figure 4.3).
As stated in Annex II and Ferreira et al. (2014) as well as other previous studies of gene
expression in CLL (Klein et al., 2001; Rosenwald et al., 2001) and re-analyzed here using
limma (Smyth, 2005; Ritchie et al., 2015), mean gene expression values show only very
little difference between the two types, see right panel of figure 4.3. Genes were considered
differentially expressed when their Benjamini-Hochberg corrected p-values (Benjamini &
Hochberg, 1995) were smaller than 0.05 and their absolute M-values were greater than 1.
These observations suggest that gene expression variability across patients can be an
important factor to distinguish the two disease subtypes, for which differential mean
expression is not discriminatory.
Figure 4.3: Gene expression variability comparison of U-CLL and M-CLL. Scatterplots comparing
U-CLL and M-CLL where each data point represents a single gene. Lighter colors indicate higher densities
of data points in the corresponding regions of the plot. Genes with statistically significant p-values at an
false discovery rate (FDR) of 5% are highlighted by circles. The gray dashed line represents the identity
line. Left panel: Scatterplot of CV across patients in the two disease subtypes. Genes with statistically
significant differential variability according to the F-test are highlighted. Middle panel: Scatterplot of
EV across patients in the two disease subtypes. Genes with statistically significant differential variability
according to the F-test are highlighted. Right panel: Scatterplot of mean expression levels across patients
in the two disease subtypes. Genes with statistically significant differential expression are highlighted.
Figure taken from Ecker et al. (2015).
As shown in figure 4.3, a substantial number of genes display higher variability across
U-CLL patients compared to M-CLL patients. Applying an F-test (Snedecor & Cochran,
1989) with a FDR of 5% to assess statistical significance we found 2,025 genes with
significantly increased variance in U-CLL whereas only 360 genes are significantly less
variable in this subtype compared to M-CLL. Repeating these analyses with the smaller
and less comprehensive datasets of Fabris and Haslinger used for validation, we confirmed
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the result of increased expression variability in U-CLL, as can be seen in table 4.2 and
supplementary figure SF3 in Annex I).
Table 4.2: Column ‘all’ lists the number of all genes, column ‘sig’ those with statistically significant
p-values corresponding to the F-test (FDR=0.05). The significant genes are highlighted in figure 4.3 and
SF3 correspondingly.
Increased var in M-CLL Increased var in U-CLL
all sig all sig
ICGC 6,425 360 13,871 2,025
Fabris 4,936 64 9,793 172
Haslinger 3,829 44 6,459 106
We found a strong correlation between the CV of the CLL subtypes in the patient cohorts
of the ICGC and the data of Fabris (Pearson r = 0.67 in M-CLL and r = 0.66 in U-CLL,
p < 2.2 × 10−16 in both, see also supplementary figure SF4 in Annex I), and also for
the SD (Pearson r = 0.75, p < 2.2 × 10−16, supplementary figure SF4). The differences
between the CV-values in M-CLL and U-CLL for genes in the two cohorts of the ICGC
and Fabris are significantly correlated as well (Pearson r = 0.28, p < 2.2× 10−16, supple-
mentary figure SF4).
Furthermore, we observed a very high correlation of differential variability measured ei-
ther by CV or EV differences (ICGC: Spearman correlation ρ = 0.91; Fabris: Spearman
correlation ρ = 0.93; p < 2.2 × 10−16 in both; supplementary figure SF5 in Annex I).
Comparing the top 500 genes with increased variability in U-CLL in each dataset (see
supplementary table ST1 table s1.html) we found a significantly higher than expected
overlap (69 genes, hypergeometric test, p < 2.2× 10−16).
Concluding, our results are reproducible in the two datasets investigated, both in terms
of the correlation of the measurements of global expression variability of all genes, and in
the comparison of ranked lists of the top differentially variable genes, and are therefore
very unlikely to be caused by batch effects.
4.1.4 Gene Expression Variability and DNA Methylation
In the next step, we asked if the differences we observe in expression variability might
be explained by differential DNA methylation. For the gene expression dataset of the
ICGC matched DNA methylation data are available (Kulis et al., 2012). Therefore,
we compared the methylation profiles of the top 500 differentially variable (DV) genes
with increased variability in U-CLL (supplementary table ST1 table s1.html) but could
not observe any strong and clear trend of different methylation levels between the two
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subgroups M-CLL and U-CLL, not in the genes’ promoters, neither in their bodies (see
figure 4.4 and supplementary figure SF6 in Annex I).
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Figure 4.4: Methylation values of the top 500 genes with increased variability in U-CLL. Scatterplots
comparing U-CLL and M-CLL. Lighter colors indicate higher densities of data points in the corresponding
regions of the plot. The gray line represents the identity line, the blue dashed line shows a fitted regression
line. Left panel: Promoter methylation. Right panel: Gene body methylation.
Figure taken from Ecker et al. (2015).
Additionally, we performed a region-based analysis of differential methylation between
M-CLL and U-CLL (see section 3.1.3) in order to find out if methylation differences could
relate to the differences in expression variability between the two subtypes. We identified
618 regions showing significant hypermethylation in U-CLL and 746 regions showing
significant hypermethylation in U-CLL, but could again not find a direct relationship
between DNA methylation and gene expression variability. Furthermore, neither the
promoters nor the bodies of the top 500 DV genes with increased expression variability
in U-CLL are represented within differentially methylated regions at higher rates than
would be expected by chance, as can be seen in table 4.3.
Table 4.3: Results of hypergeometric tests assessing the overlap between genes within differentially
methylated regions and genes with increased expression variability in U-CLL. The column ‘all’ lists the
numbers of genes for which their promoters or gene bodies have been identified to lie within differentially
methylated regions. Column ‘DV’ shows the number of the genes reported in the previous column which
are also contained in the list of the top 500 genes with increased variability in U-CLL for which methy-
lation measurements are available (n = 491). Column ‘p’ contains the p-values of the hypergeometric
test evaluating if the overlap between the gene lists is bigger than expected by chance.
Hypermethylated in M-CLL Hypermethylated in U-CLL
Region all genes DV genes p-value all genes DV genes p-value
Promoter 381 15 0.2647 238 8 0.5174
Gene body 165 5 0.6296 173 6 0.4989
1The study of Landau et al. (2014b) was published after our work (Ecker et al., 2015) was accpeted for publication.
According to a study published by Lam et al. (2012), also DNA methylation variability in
CLL does not have an obvious association with gene expression. Landau et al. (2014b)1
however, employing a different approach to measure DNA methylation variability by cal-
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culating the proportion of discordant reads in regions of subsequent CpGs using whole
genome bisulfite sequencing (WGBS) and reduced representation bisulfite sequencing
(RRBS) data, found that methylation variability in gene promoters was negatively corre-
lated with average gene expression levels, and positively correlated with interindividual
gene expression variability. However, as they stated in their study as well, it is difficult
to say which of the two components is driving the correlation they identified, because
of the strong negative dependence of expression variability on mean expression levels.
Landau et al. (2014b) quantified gene expression variability using the CV and calculat-
ing the entropy of gene expression, without taking differing mean expression levels into
account. Using an additional single-cell approach, they observed an association of dis-
ordered methylation with a decoupling of the expected relationship between promoter
methylation and gene expression (described in section 1.2 and shown in figure 1.2).
Taking these results together, the relationship between DNA methylation and gene ex-
pression variability seems to be complex and difficult to disentangle. It is very likely
that multiple layers of epigenetic modifications such as for example histone marks are
involved in the process of regulating gene expression, or gene expression variability, and
different dynamics of different epigenetic processes could contribute to this complexity.
For example, it could also be possible that DNA methylation serves to poise genes for
expression in response to future events (Lam et al., 2012).
4.1.5 Functional Analysis of Differentially Variable Genes
We performed functional enrichment analysis on the top 500 genes with increased vari-
ability in U-CLL in order to detect if the increased variability in U-CLL affects specific
biological processes. First of all, we identified the top 500 genes with increased variability
in U-CLL in the ICGC dataset. We excluded all genes with non-significant p-values ob-
tained by the F-test, and considered furthermore only genes with consistently increased
variability in U-CLL across all three variability measures employed, that is, CV difference,
EV difference, and the F-test (see section 3.1.2). The remaining genes were ordered by
their CV differences and EV differences respectively. In the case of the dataset of Fabris
only 172 genes reached statistical significance, therefore we did not apply the p-value
cutoff here in order to achieve a comparable list of 500 genes. Both lists are available in
supplementary table ST1 table s1.html.
Functional enrichment analyses were then performed on these lists using both the webtool
DAVID (Huang et al., 2009) and Bioconductor packages (Falcon & Gentleman, 2007;
Gentleman, 2015), see section 3.1.4 for further details.
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Looking at the top 500 genes with increased variability in U-CLL patients of the ICGC
study (see supplementary table ST1 table s1.html) we observed a significant enrichment
for processes related to the cell cycle, hemopoiesis, multicellular organismal processes,
wounding, and development of the immune system and immune system processes. Al-
together, we found 49 significantly enriched gene ontology (GO) terms and pathways at
an FDR of 5% shown in supplementary table ST3 table s3.html. Repeating the same
analysis using the smaller dataset of Fabris, which interrogates less genes and comprises
a smaller number of samples, we were able to recapitulate these findings to a certain
extent, with significant enrichments in three immune system processes and, although not
reaching statistical significance with a FDR of 5%, also in hemopoiesis, development,
wounding, and cell proliferation (see supplementary table ST4 table s4.html).
In order to gain a deeper understanding of the functional context of genes with signif-
icantly increased gene expression variability in U-CLL we performed network analyses.
For these analyses we used the top 500 genes with increased variability in U-CLL in
common in both datasets (ICGC and Fabris). We applied the same strategy as described
above, with the only difference that we did not cut the list after the first 500 genes
within each dataset separately but when reaching 500 genes in common in both datasets.
The list of these top 500 genes is also available in supplementary table ST1 table s1.html.
We mapped these top genes with increased variability in U-CLL to Entrez gene identifiers
resulting in 494 unique Entrez genes in order be able to cross them with a B cell specific
functional interaction network published by Lefebvre et al. (2010). This interactome as-
sembles B cell specific transcriptional and post-translational molecular interactions that
was constructed by Lefebvre et al. (2010) using a collection of 254 B cell gene expres-
sion profiles derived from normal and malignant B-cells of primary tumor samples and
cell lines. The complete network contains 5,748 nodes (genes) and 64,600 unique edges
(interactions). We extracted a subnetwork of the top genes with increased variability in
U-CLL and included their direct neighbors into the subnetwork, considering only genes
connected with at least two other genes. The resulting network contains 892 genes con-
nected by 3,390 edges.
We identified five network modules in the network of 892 genes by using Gephi (Bastian
et al., 2009) and Louvain’s method (Blondel et al., 2008), an algorithm to detect com-
munities in large networks based on modularity known to produce results of high quality
(Newman, 2012; Lancichinetti & Fortunato, 2009) and which has been successfully ap-
plied in different network fields (Greene et al., 2010; Zhang et al., 2010; Meunier et al.,
2009; Amir et al., 2013; Newman, 2012). Six genes were not mapped to any of the other
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network modules and were therefore excluded from the subsequent functional enrichment
analyses of network modules. Figure 4.5 shows the network with the five network modules
highlighted in different colors.
Figure 4.5: Network representation of genes with increased variability in U-CLL in the context of a B cell
specific network [36]. Node sizes are determined by the degrees of the nodes, that is, big nodes represent
highly connected genes. Different network modules are highlighted in different colors.
Figure taken from Ecker et al. (2015).
Functional enrichment analyses of the identified network modules showed that every
module is highly enriched in biological processes and pathways, further confirming our
results of biological functions affected by increased expression variability in U-CLL, and
giving a deeper insight into these processes and pathways and the genes involved (see
supplementary table ST5 table s5.html and table 4.4 for a summary of the results).
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Table 4.4: Functional enrichment of network modules. The first column shows the number of genes
contained in every module of the network. The second column shows the top terms for which the
corresponding module is enriched. The last column lists highly connected genes (degree ≥ 35) of the
corresponding module ordered alphabetically.
Genes Top enriched terms Highly connected genes
Module 1 135 Cell death, cell differentiation and de-
velopment
BCL2L1, PRKCA
Module 2 261 Ribosome, translation LMO2, NR3C1, POU2F1,
RARA, RBPJ, RPL14, YY1
Module 3 160 Signal transduction, cell communica-
tion, membrane, protein kinase activ-
ity, phosphorylation
ARHGEF6, BCL3, CAV1,
CRK, FGFR1
Module 4 151 Transcription factor activity, gene ex-
pression, DNA binding
CCL2, JUND, STAT1
Module 5 179 Cell cycle ATF2, CCNB2, CDC20,
CDC25A, CREB1, E2F4,
ESR1, FOXM1, MIKI67,
MYC, POU2F2, RBL2, SP3,
TYMS, UBE2C, VRK1
The first network module is heavily enriched for cell death and apoptosis, and shows fur-
thermore enrichments for cell differentiation, cellular development processes, and system
and multicellular organismal development as well as cancer pathways. The most con-
nected gene in this module is PRKCA (protein kinase C alpha), a kinase involved in cell
differentiation, cell cycle checkpoint and cell volume control which also plays an impor-
tant role in the growth and invasion of cancers (Koivunen et al., 2006) and is known to act
as an anti-apoptotic agent in leukemic B cells by phosphorylating BCL2 (Ruvolo et al.,
1998). Precisely BCL2L1 (B cell CLL/lymphoma 2 like 1), a member of the BCL2 fam-
ily, is the second most connected gene in the module, and has also been suggested to play
an important role in B cell apoptosis and CLL (Jiang & Clark, 2001). Two alternatively
spliced transcript isoforms of the gene are currently known, where the longer isoform acts
as an apoptotic inhibitor and the shorter one as an apoptotic activator (Boise et al., 1993).
Module two of the network, which is enriched for the ribosome and translation as well as
transcription, contains the biggest hub of the network, POU2F1 (POU class 2 homeobox
1), a transcription factor which has been associated with the cell cycle (Roberts et al.,
1991; Segil et al., 1991) and is involved in the activation of immunoglobulin genes (Lee
et al., 2001). POU2F1 has also been related to the deletions on chromosome 11 in CLL
(Auer et al., 2005).
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Further highly connected genes in module two are the glucocorticoid receptor NR3C1
(nuclear receptor subfamily 3, group C, member 1) which regulates developmental genes
and affects inflammatory response, cellular proliferation and differentiation, and has also
been related to the cell cycle (Lu et al., 2006), and YY1 (yin yang 1), a transcription
factor involved in the activation and transcription of ribosomal proteins (Voronina et al.,
2008), development and differentiation, as well as tumorigenesis (Sui, 2009). The gene has
been related to a plethora of human cancers and hematopoietic malignancies (Bonavida
et al., 2011; Nicholson et al., 2011).
Other smaller hubs in module two are the gene LMO2 (LIM domain only 2 rhombotin-like
1), an oncogene which plays a crucial role in hematopoietic development and leukemia
(Warren et al., 1994; Davenport et al., 2000), and RPL14 (ribosomal protein L14) and
RARA (retinoic acid receptor alpha), both associated with translation (Odintsova et al.,
2003; Chen et al., 2008).
The signaling module (module three) in the network shows – beside heavy enrichments
for signal transduction and cell communication – localization to the plasma membrane
and further enrichments for kinase activity and phosphorylation. One of the highly con-
nected genes within this module is CAV1 (caveolin 1), a gene strongly related to signal
transduction which is able to affect cell function and cell fate (Shatz & Liscovitch, 2004;
Engelman et al., 1998) and has furthermore been described to play a significant role in
CLL progression (Gilling et al., 2012).
Beside further important signaling genes like FGFR1 (fibroblast growth factor receptor 1),
a cell-surface receptor playing an essential role in development, cell proliferation, differ-
entiation and migration (Groth & Lardelli, 2002) which has also been related to clinical
outcome in CLL (Gilling et al., 2012), another highly connected gene in network module
three is BCL3 (B cell CLL/lymphoma 3) which is involved in the activation of NF-κB
target genes, plays a role in the regulation of cell proliferation (Na et al., 1999), and has
been described to stimulate AP1 (activator protein 1) proteins (Na et al., 1999).
In the context of signaling in CLL, it is important to mention that the BCR – also con-
tained in network module three, although not among the most highly connected genes
in the module – has been reported to exhibit crucial differences in M-CLL and U-CLL.
As also described in section 1.5 and Annex II, BCR signaling leads to transcriptional
responses in CLL cells that have been strongly associated with cell activation, enhanced
cell cycle entry, and progression of the disease. After stimulation of the BCR in CLL, key
molecules of the BCR signaling cascade (for example ZAP70 and SYK ) are recruited,
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which leads to the phosphorylation of the B cell linker protein, a central node for intra-
cellular signaling (Zenz et al., 2010).
In U-CLL, a higher proportion of stereotyped rearrangements and biased somatic mu-
tation patterns could be observed in the BCR (Messmer et al., 2012), and the BCR in
U-CLL has been reported to be usually polyreactive to autoantigens, for example pro-
teins or lipids generated by oxidative stress (Chiorazzi & Ferrarini, 2003, 2011). It was
concluded that in U-CLL the BCR signaling pathway is more readily stimulated by cross-
linking (Rosenwald et al., 2001; Zenz et al., 2010; Guarini et al., 2008). Indeed, several
genes have been shown to be exclusively modulated in U-CLL cells upon BCR activation,
indicating that antigenic stimulation plays a key role in the progression of CLL, as the
BCR signaling pathway is associated with cell-cycle progression and survival of malignant
B cells (Chiorazzi & Ferrarini, 2011; Guarini et al., 2008).
However, there is some controversy about the differences of the BCR in the two disease
subtypes in the literature. Herishanu et al. (2011) for example showed evidence of BCR
activation in both U-CLL and M-CLL cells in vivo, at least in the lymph node environ-
ment. Similar results have been reported by Krysov et al. (2012) and Pede et al. (2013),
who found both M-CLL and U-CLL cells to respond to BCR activation, and concluded
that the difference observed in freshly isolated peripheral blood CLL cells is caused by
differences in in vivo triggering of the BCR (Pede et al., 2013), consistent with the ob-
servation of Herishanu et al. (2011) that the transcriptional differences are small in cells
isolated from lymph nodes.
Differences between M-CLL and U-CLL in the response of the BCR could lead to a bias
due to isolation procedures in in vitro experiments, as positive antibody selection acti-
vates signaling pathways and induces gene expression changes not inherent to the cell but
caused by the activation of the BCR. In any case, the documented relationship between
expression variability and adaptability in response to perturbations (see section 1.3) sug-
gests that the higher heterogeneity present in this disease subtype might contribute to
the increased response in signaling reported for U-CLL.
Interestingly, in the ICGC study of Ferreira et al. (2014) in which we investigated the
transcriptome of CLL (see also Annex II), splicing changes were identified in several genes
of the BCR pathway. These changes could possibly contribute to the observed variability
in signaling in U-CLL, as there is evidence of an association between alternative splicing
and gene expression variability (Wang & Zhou, 2014).
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Signaling has also been reported to be deregulated in CLL and especially in U-CLL by
others (Chuang et al., 2012; Guarini et al., 2008; Landau et al., 2013), and signaling path-
ways were therefore suggested as potential targets for treatment strategies (Zenz et al.,
2010; Kipps, 2007).
In network module four, which is enriched for transcription factor activity, DNA bind-
ing and gene expression, the most connected gene is JUND (jun D proto-oncogene), a
member of the above mentioned AP1 transcription factor complex that regulates lym-
phocyte proliferation (Meixner et al., 2004). It has been suggested to protect cells from
P53 induced senescence and apoptosis (Weitzman et al., 2000) and has an influence on
tumorigenesis and cancer progression (Eferl & Wagner, 2003).
Two other highly connected genes of network module four are CLL2 (chemokine C-C
motif ligand 2), a gene involved in immunoregulatory and inflammatory processes (Xu
et al., 1996) which has AP1 binding sites in its promoter (Wolter et al., 2008), and STAT1
(signal transducer and activator of transcription 1, 91kDa), a transcriptional activator
which plays an important role in lymphocyte proliferation and survival as well as cell
viability in response to stimuli and pathogens (Lee et al., 2000). In CLL STAT1 has
furthermore been shown to be related to resistance to DNA-induced apoptosis (Vallat
et al., 2003) and to be aberrantly phosphorylated on serine residues (Frank et al., 1997).
The most important gene of the cell cycle module (module number five) is MYC (v-myc
avian myelocytomatosis viral oncogene homolog), a transcription factor that activates
the expression of many genes but has also been suggested to act as a transcriptional
repressor (Pelengaris et al., 2002). It is a key regulator of cell cycle entry (Krysov et al.,
2012), has a direct role in the control of DNA replication (Dominguez-Sola et al., 2007),
and regulates differentiation, cell growth and apoptosis by modulating the expression of
distinct target genes like for example the downregulation of BCL2 among other apop-
totic pathway genes (Pelengaris et al., 2002; Lu¨scher, 2001; Nilsson & Cleveland, 2003).
Deregulation of MYC has been shown to be very strongly related to tumor formation
(Lu¨scher, 2001), and the expression of MYC is altered in many types of cancer (Nilsson
& Cleveland, 2003), including CLL (Rana et al., 2014), where it has been demonstrated
that MYC and its target genes are overexpressed in lymph nodes compared to blood
cells (Herishanu et al., 2011), and that increased basal expression of MYC in CLL cells
is associated with progressive disease (Zhang et al., 2010).
Further highly connected genes in the cell cycle module are FOXM1 (forkhead box protein
M1) which plays a key role in multiple facettes of cell cycle progression and is known as
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a proto-oncogene which contributes to both tumor initiation and progression in leukemia
(Wierstra & Alves, 2007; Mencalha et al., 2012), and has been shown to be upregu-
lated in many tumors, and other key regulators of the cell cycle such as ESR1 (estrogen
receptor 1) which is known to be involved in cell growth, cellular proliferation and dif-
ferentiation (Shupnik, 2004), RBL2 (retinoblastoma-like 2), a progression marker gene
in CLL (Fa¨lt et al., 2005), and E2F4 (E2F transcription factor 4, p107/p130-binding),
a gene which has been shown to be deregulated in rapidly growing B cell lymphomas.
The latter two are also interacting key regulators of the cell division cycle (Sardet et al.,
1995). Beside many other cell cycle related genes highly connected in network module five
it also contains the gene MKI67 (marker of proliferation Ki-67), a widely used marker of
cellular proliferation in human tumors and a strong predictor of survival in CLL (Bruey
et al., 2010).
The heavy enrichment for cell cycle related genes and functions among the genes with in-
creased variability in U-CLL is especially interesting because historically, CLL was viewed
as a purely accumulative disease of malignant cells with a defect in apoptosis (Rosenwald
et al., 2001; Rozman & Montserrat, 1995; Caligaris-Cappio & Hamblin, 1999). Recent
studies however showed that proliferation plays an important role in CLL progression
(Messmer et al., 2005; Guarini et al., 2008; Chiorazzi et al., 2005; Obermann et al., 2007;
Krysov et al., 2012). A study of Messmer et al. (2005) measuring cell kinetics using a
nonradioactive method showed for example that the above mentioned cell cycle marker
MKI67 is expressed in CLL in vivo.
Obermann et al. (2007) showed two years later that although the majority of CLL cells
are resting in G0 phase, a considerable number of cells have proliferative potential, with
a significant subpopulation of cells residing in early G1 phase, probably contributing to a
more aggressive biological behavior with increasing numbers. In their study the amount
of cells with proliferative potential indicated by the expression of the cell proliferation
marker MCM2 (minichromosome maintenance complex component 2) – a key compo-
nent in genome replication (Tye, 1999; Chong et al., 1996)) – was far higher than the
number of proliferating cells expressing MKI67. The progression into the G1 phase is
particularly important as cells in the G1 phase are known to be more prone to external
stimuli to further progress into cell cycle (Obermann et al., 2007), which relates again to
the increased variability observed here, and to the significant enrichment of signaling in
the network of highly variable genes in U-CLL.
Again, the BCR seems to play an important role in this context. BCR stimulation via
antigens has been demonstrated to induce G1 progression, proliferation and enhanced
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cell survival in U-CLL patients (Longo et al., 2007; Deglesne et al., 2006). Several studies
found specific expression of proliferative pathways in U-CLL (Kanduri et al., 2010; Guar-
ini et al., 2008; Herishanu et al., 2011), while M-CLL showed an increase of apoptotic
levels in stimulated cells (Guarini et al., 2008). Related to these observations, Messmer
et al. (2005) reported a wide range of different cell proliferation and apoptosis rates across
CLL patients, further supporting the findings of increased variability in the correspond-
ing network modules analyzed here.
Consistent with the observation of increased proliferative potential in U-CLL, it has more-
over been shown that the telomeres of U-CLL cells are much shorter than those of cells
obtained from age-matched normal donors, but also compared to M-CLL cases (Hoxha
et al., 2014; Sellmann et al., 2011; Damle et al., 2004; Rampazzo et al., 2012), indicating
an extensive history of cell division, and pointing to the activation of pathways induc-
ing proliferation in U-CLL cells. Telomere shortening is also contributing to genomic
instability and could enhance the clonal evolution predominantly observed in U-CLL (see
section 1.5.2).
Furthermore, Rana et al. (2014) reported a deregulation of circadian clock genes in CLL.
The aberrant expression of these genes could contribute to genomic instability and ac-
celerated proliferation due to the aberrant expression of downstream targets involved in
cell proliferation and apoptosis (Rana et al., 2014).
Some authors even suggested that proliferation and not apoptosis inhibition might be
the main criterion determining clinical outcome in CLL, and cell cycle inhibitors have
already entered clinical trials as therapeutic agents (Herishanu et al., 2011; Obermann
et al., 2007; Flynn et al., 2015).
Concluding, U-CLL patients show increased variability in cell proliferation directly af-
fected by key cell cycle regulation genes, and furthermore in cell differentiation and de-
velopment, cell death, and intercellular communication and signaling, all of which could
be impacting the aggressiveness and adaptability of this subtype, possibly explaining the
worse clinical outcome of U-CLL.
4.1.6 Classification of Patients by Gene Expression Variability
The previously described results showing considerable differential gene expression vari-
ability between the two subtypes of CLL suggest that measurements of gene expression
heterogeneity might be a distinctive feature of M-CLL and U-CLL that can be used for
the separation of the two subtypes in a classification approach.
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As we have stated previously here and in Ferreira et al. (2014) and had also been reported
by others before (Klein et al., 2001; Rosenwald et al., 2001), gene expression data “as is”
is not sufficient to cluster patients into the two disease subtypes M-CLL and U-CLL. For
example, considering the gene expression levels of all genes from the ICGC gene expression
dataset (n = 20, 149) and applying a standard hierarchical clustering, no separation of
the two disease subtypes is obtained, as can be seen in figure 4.6.
Figure 4.6: Hierarchical clustering of gene expression data. Heatmap representing a clustering of the
CLL samples of the ICGC study. Dark blue colors in the heatmap represent short distances, light colors
indicate large distances. U-CLL samples are colored in orange, M-CLL samples in dark magenta, and
healthy cells in blue (memory B cells), green (naive B cells) and black (CD19+ B cells).
Figure taken from Ecker et al. (2015).
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Nevertheless, applying a kind of “de-noising” strategy on the expression data allowed us to
group the patients reasonably well into the two subtypes via unsupervised clustering. This
approach works by aggregating patients into groups by extracting five random U-CLL
patients and another five random M-CLL patients as long as sets of five can be made
without repeating samples in the groups, such that a new cohort of “superpatients” is
produced, in which half are M-CLL and the other half U-CLL superpatients. These
superpatients represent constructs of aggregated samples that help to remove noise from
the data. Indeed, when we calculated the mean expression values for the superpatients,
we were now able to separate the two groups by hierarchical clustering, as can be seen in
figure 4.7.
Figure 4.7: Hierarchical clustering of superpatients. Heatmaps representing the clustering of superpa-
tients into M-CLL and U-CLL, based on aggregate measures. Left panel: Superpatient clustering based
on mean expression values. Right panel: Superpatient clustering based on the CV. Results very similar
to the figure on the right were obtained when using other measurements of variability such as the EV,
SD, interquartile range (IQR) or different distance measures (data not shown).
Figure taken from Ecker et al. (2015).
This approach provides the additional advantage that also variability of gene expression
can be measured, which is not possible for individual patients when not having multiple
samples of the same patient across different time points. A hierarchical clustering based
on variability measurements also separates the two subgroups very well (see figure 4.7).
Changing the number of patients used to create the superpatients like for example taking
seven or ten random samples instead of five did not generally alter the results. However,
as the superpatient approach relies on random subsampling of the patients, the results
of the hierarchical clusterings can vary after every new run of patient aggregation. This
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approach should therefore not primarily be taken as a stable classification method but
more as a demonstration of the power of the concept. The fact of being able to separate
the two disease subtypes by applying the superpatient method indicates that the previ-
ous observations of gene expression profiles not being able to distinguish the two disease
subtypes are probably caused by noise and variation of both technical (Tu et al., 2002;
Gentleman et al., 2005) and biological (as described in this work) origin which is present
in transcriptomic data.
To further investigate this observation, we sought to apply an unbiased classification
method and trained a random forest classifier (Breiman, 2001; Liaw & Wiener, 2002) on
the ICGC gene expression data using 1,000 trees. Subsequently, we used this classifier
to predict the CLL subtypes of the patients in the dataset of Fabris. To establish the
feature sets used in the random forest classification approach we considered only genes
present on both microarray platforms of the two different studies (n = 12,307). In order
to robustly estimate error rates, we repeated the analysis 1,000 times.
First, mean expression values of the 12,307 genes present in both datasets were used as
features. The resulting random forest classifier based on gene expression values was able
to classify patients correctly, with a mean AUC of 0.90, see figure 4.8 and table 4.5.
Next, based on the observations we made when reducing gene expression noise (see above),
we repeated this analysis using only the top 500 genes with most different mean expres-
sion levels between M-CLL and U-CLL corresponding to their absolute M-values. The list
of these genes can be found in the first column of supplementary table ST2 table s2.html.
The prediction of the disease subtypes in Fabris’ dataset based on the classifier trained
on the ICGC data improves considerably when using the top 500 differentially expressed
genes, now reaching a mean AUC of 0.96 (see figure 4.8 and table 4.5).
Finally, inspired by our promising results on the importance of the variability of gene
expression as a defining characteristic of M-CLL and U-CLL, we created random forests
using the top 500 most differentially variable genes. Here, we only included genes with
Benjamini-Hochberg corrected p-values (Benjamini & Hochberg, 1995) smaller than 0.05
and furthermore we only took genes into account which showed consistently increased
or decreased variability according to all three differential variability measures we applied
(that is, the CV difference, the EV difference, and the F-test) and ordered the list of the
remaining genes once by their absolute CV differences, and once by their absolute EV
differences. The top 500 most differentially variable genes corresponding to the CV and
EV are available in column two and three of supplementary table ST2 table s2.html).
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We defined a new feature to measure expression variability for each gene in each patient
as the distance from a gene’s expression value xi to the median of that gene i over the
population x˜i, see formula 4.1.
disti = |xi − x˜i| (4.1)
We trained our random forest classifier applying this measure to the top 500 differentially
variable genes on the data of the ICGC aiming again to predict the disease subtype of the
patients in Fabris’ dataset. Strikingly, this classifier based on gene expression variability
performs equally well as the one based on differential expression, with a mean AUC
of 0.96, and an even smaller standard deviation thereof, indicating more robust results
compared to using mean expression levels (see figure 4.8 and table 4.5).
Figure 4.8: Random forest classifier results. Boxplots showing the distribution of AUC values of 1,000
independent runs per classifier.
Figure taken from Ecker et al. (2015).
Classifiers using feature sets consisting of 500 randomly selected genes perform signifi-
cantly worse, both in the case of using mean gene expression levels as well as when using
the variability measure introduced above. The results of the different classifiers are shown
in figure 4.8 and table 4.5.
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Table 4.5: Random forest classifier results. AUC values of 1,000 independent runs per classifier. The first
three rows show the results of the classifier when it is feeded with gene expression values (exprs values).
The last three rows show the result of the classifier when the features are selected based on expression
variability, and gene-wise variability was quantified by the above introduced variability measure which
calculates the absolute distance of a gene’s expression value from the population median (var values).
Mean Median Min Max SD
All genes (exprs values) 0.9028 0.9144 0.6244 0.9977 0.0578
Top 500 DE genes (exprs values) 0.9637 0.9653 0.8906 0.9965 0.0162
500 random genes (exprs values) 0.7000 0.7014 0.3258 0.9867 0.1218
Top 500 DV genes based on CV (var values) 0.9596 0.9601 0.9352 0.9769 0.0064
Top 500 DV genes based on EV (var values) 0.9635 0.9635 0.9277 0.9850 0.0079
500 random genes (var values) 0.7172 0.7118 0.5168 0.9161 0.0736
In summary, our initial results on the available datasets suggest that expression vari-
ability can classify the two clinical subtypes of CLL very well, pointing to a potential
relation between expression variability and disease aggressiveness. If these results can be
confirmed by follow-up studies with larger datasets, it will be interesting to explore the
use of expression variability for the classification of other disease states as well.
4.1.7 Interpretation and Further Discussion
As has already been reported for heterogeneity in CLL at the genetic and epigenetic level
(Kleppe & Levine, 2014; Swanton & Beck, 2014; Oakes et al., 2014; Landau et al., 2013,
2014b), increased variability in CLL worsens clinical outcome, perfectly in line with our
findings of increased gene expression variability in the more aggressive type of the disease,
which had not been investigated before. Taking these observations into a more clinical
point of view, monitoring gene expression heterogeneity during disease course might be
an advantageous strategy to improve therapeutic decisions and risk prediction in CLL
patients. Additionally, the further assessment of the implications of variability in CLL
might gather important insights into the disease and provide knowledge for new combi-
natorial therapies (Landau et al., 2014a).
The patients included in this study did not receive any prior CLL treatment, but it has
to be noted that we cannot exclude the possibility of (other) drug therapy that U-CLL
patients might have received, the age of the individuals, or eventual technical factors to
contribute to the observed increase in interpatient variability in U-CLL.
What can however be excluded as a confounding factor in this work are cell type composi-
tion effects, as CLL tumor samples can be obtained at near-complete purity with ≥ 95%
neoplastic cells (Kulis et al., 2012; Ferreira et al., 2014). Additionally, CLL genomes are
nearly diploid and gene expression variability is therefore unlikely to be influenced by
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somatic copy number variation (Landau et al., 2014b), while other genetic and epigenetic
alterations, as described previously (see section 1.3 and 1.5.2), probably play a role to-
gether with gene expression variability in generating phenotypic diversity in CLL.
Interestingly however, genetic heterogeneity in terms of higher frequencies of somatic
mutations has been reported to be predominantly associated with M-CLL, not U-CLL
(Landau et al., 2013; Puente et al., 2011; Quesada et al., 2011), while clonal evolution
and increased methylation heterogeneity have been associated to U-CLL (Oakes et al.,
2014; Stilgenbauer et al., 2007; Herishanu et al., 2011; Landau et al., 2014a; Gunnarsson
et al., 2011), the subtype of the disease in which we observe increased gene expression
variability in our work as well.
Another notion that has to be made is that for human data not much is yet known about
the translation of cellular RNA expression variability into protein levels (Satija & Shalek,
2014), although several studies tried to elaborate on the question of the relationship be-
tween gene expression variability and protein fluctuations in model systems (Ozbudak
et al., 2002; Blake et al., 2003; Kaern et al., 2005; Raj & Van Oudenaarden, 2008; Gold-
ing et al., 2005; Kierzek et al., 2001; McAdams & Arkin, 1997).
Finally, our observation of increased expression variability across patients in U-CLL is
likely to relate to single cell heterogeneity within patients as explained in section 1.3.
Actually, relying on this hypothesis, we can link the variability observed across individ-
uals to the worse prognosis for U-CLL patients, which can be attributed to the presence
of cellular heterogeneity and hence aggressiveness, adaptability, and increased resistance
to therapy in this disease subtype. However, to verify this hypothesis, larger datasets
comprising multiple samples per patient and/or time series, and in particular single cell
data allowing the detailed study of transcriptional variability will be an invaluable new
source of complementary information.
The here presented work is the first systematic exploration of gene expression variability
in CLL. Our results provide important additional biological insight into the mechanisms
of the disease and uncover previously unappreciated dynamics present in CLL. Based on
these findings it might be possible in the future to develop better prognostic tools and
new therapeutic strategies improving patient outcome in CLL.
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4.2 Variability in Normal Blood Cells
4.2.1 Overview
Blood cells, as explained in section 1.3.2, exhibit a remarkable variability in terms of
size and characteristics. If two sister cells are separated directly after cell division and
get cultured under identical conditions, they can build colonies of different blood cell
types, or of the same cell type, but in distinct amounts (Alberts et al., 2004). In the
programming of cell division as well as in the process of determining the differentiation
branch followed, and in the gradual regulation of the multicellular system as a whole in
response to changes in the environment, stochastic processes at the level of individual
cells are involved (Hume, 2000; Satija & Shalek, 2014; Enver et al., 1998; Chang et al.,
2008). To fully understand these processes and the interplay between different layers of
gene regulation as well as their heterogeneity they need to be analyzed in a combined way.
We used a dataset of the Human Variation Epigenome Project of BLUEPRINT (Adams
et al., 2012) to analyze variability in DNA methylation and gene expression data of mono-
cytes, neutrophils and T cells derived from 48 healthy individuals (see also section 3.2.1).
The dataset of this project will be extended to 200 individuals in the future. An overview
of the data can be seen in figure 3.1. The pilot dataset of 48 individuals was used to
develop the methodology and analysis pipelines for the BLUEPRINT project and to pro-
vide hypothesis to be tested specifically later in the project with the larger dataset.
In the following we discuss how to measure and compare variability across different cell
types in distinct data types and present initial results obtained from the analysis of
the pilot dataset, showing that neutrophils exhibit patterns of increased interindividual
variability compared to monocytes and T cells.
4.2.2 Analysis of Variability in Different Biological Data Types
As here we want to analyze both DNA methylation microarray data and RNAseq data
to investigate DNA methylation and gene expression variability as well as their interre-
lationships, we needed to establish a methodological framework that is able to deal with
both microarray and sequencing data and to produce comparable results across distinct
biological data types.
To this aim, we used DiffVar (Phipson & Oshlack, 2014), a recently developed method to
measure differential variability based on limma (Smyth, 2005), a sophisticated R software
package originally developed for the analysis of differential gene expression in microarrays
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that has been continuously extended during the past decade and is now also able to deal
with RNAseq and DNA methylation data (Ritchie et al., 2015).
Applying limma is of particular advantage here, as we want to analyze both gene expres-
sion and DNA methylation data, and using the same methodological basis and statistical
approach for the different types of analysis – that is differential variability in DNA methy-
lation microarray data and differential variability in gene expression data obtained by
RNAseq, both of which will be additionally compared to the results of classical analyses
testing for differences in mean DNA methylation and gene expression levels – makes the
results consistently comparable across all analyses performed.
A particular further strength of limma is that it takes advantage of the highly parallel
nature of genomic data to borrow information between gene-wise models by the use of an
empirical Bayes estimators, making the statistical conclusions more robust and reliable,
especially when the number of samples is small (Ritchie et al., 2015), which is typically
the case in genomic analyses, where the number of tested features (that is, genes or CpGs)
is orders of magnitude higher than the number of samples available.
Additionally, limma is able to incorporate a mean-variance trend into the model, which is
important as both gene expression and DNA methylation values often show some degree
of heteroscedasticity. The mean-variance relation is modeled via the so called “voom”
(“variance modeling at the observational level”) conversion (Law et al., 2014). The al-
gorithm transforms the data into normalized counts on the logarithmic scale (base 2),
and estimates the relationship between mean and variance to determine precision weights
that are subsequently incorporated to the linear model (Ritchie et al., 2015).
Moreover, as limma is based on linear modeling, it is extremely flexible and almost any
type of experimental design and customized comparisons can be handled (Ritchie et al.,
2015). As the data analyzed here was obtained from the same individuals for all cell
types (see section 3.2.1 and figure 3.1), we performed paired tests in order to rule out
confounding effects of covariates related to individuals like for example age, sex or blood
cell counts. Indeed, when we added such additional information related to individuals to
the paired model, only negligible changes of results could be observed. The overlap be-
tween significant results obtained by the model without additional covariates and models
where distinct covariates were included was greater than 99% (data not shown).
In comparisons of commonly used methods to analyze genomic data (Seyednasrollah
et al., 2015; Soneson & Delorenzi, 2013; Rapaport et al., 2013; Jeanmougin et al., 2010;
Law et al., 2014), limma is often recommended as the best choice. It has proven to
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perform extremely well in terms of the detection of true positives, low proportions of
false positives, to deal very well with differing sequencing depths and with heterogeneous
datasets, and additionally, limma is among the computationally fastest methods.
We combined the statistical framework of limma and DiffVar with further measurements
of variability taking the mean-variance relationship present in DNA methylation and gene
expression data into account to provide robust methodology to quantify and compare
DNA methylation and gene expression variability across the three cell types investigated.
Summarizing, the integration of the well-established framework of limma with additional
methods to robustly measure differential variability allows us to use the same analytical
approach and statistical framework to answer different research questions and analyze
distinct data types, thus making the results we obtain consistently comparable across all
analysis performed in this study.
4.2.3 Comparison of Statistical Methods to Analyze Differential
DNA Methylation Variability
First of all, as we want to analyze differences in variability between three distinct blood
cell types, three group-wise comparisons leading to six lists of differentially variable loci
or genes have to be made.
The comparisons:
• Monocytes versus neutrophils
• Monocytes versus T cells
• Neutrophils versus T cells
The resulting lists of significantly differentially variable sites or genes:
• Hypervariable in monocytes compared to neutrophils
• Hypervariable in monocytes compared to T cells
• Hypervariable in neutrophils compared to T cells
• Hypovariable in monocytes compared to neutrophils
• Hypovariable in monocytes compared to T cells
• Hypovariable in neutrophils compared to T cells
As stated previously, we used DiffVar (Phipson & Oshlack, 2014) for the analysis of dif-
ferential variability between the three cell types. DiffVar is implemented within limma
(Smyth, 2005; Ritchie et al., 2015) and employs a statistical approach based on the ideas
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of Levene’s z-test (Levene, 1960). It calculates variability as the distance of each data
point within a group from the group mean, as highly variable groups are characterized
by consistently large deviations from the mean, while low variability groups show small
deviations from the mean (the same concept as we used in section 4.1.6, formula 4.1). To
determine if a group is significantly more variable than another, limma’s t-test is then per-
formed on the absolute deviations from the mean (MAD-values), similar to an approach
presented by Jaffe et al. (2011), who used the MAD to assess differential variability as well.
As DiffVar is a relatively new method, we compared the results of DiffVar to those ob-
tained by other statistical methods measuring differential variability in DNA methylation
described in the literature. Bar et al. (2012, 2014) developed a mixture model approach
to test for unequal variances between groups. This approach uses empirical Bayes mod-
eling to borrow information across all genes similar to what is done in limma and claims
to be robust to deviations from normality, which is important when dealing with DNA
methylation data due to the strong bimodal distributions, as one CpG is typically either
(almost) fully methylated across the population of cells measured in a methylation exper-
iment, or mostly unmethylated (see supplementary figure SF7 in Annex I). However, the
method did not identify any significant results in our data and all other DNA methylation
datasets with which we have tested the method (data not shown).
Bartlett’s test (Bartlett, 1937) is another statistical method to test for unequal variances
that has been used for example by Teschendorff & Widschwendter (2012) to detect out-
liers of interest, but this test is – apart from being highly sensitive to outliers which is
unwanted under many circumstances – also very sensitive to departures from normality.
That is, if the data come from non-normal distributions, it may simply be testing for
non-normality. The same applies for the F-test (Snedecor & Cochran, 1989), making it
unsuited for testing differential variability in DNA methylation data.
As an alternative, the non-parametric Ansari-Bradley test (Ansari & Bradley, 1960) has
been suggested. This procedure provides a distribution-free test of the equivalence of
variances in two distributions having a common median, which is however also often
not true in DNA methylation data. As stated above, methylation values are typically
located close to the extremes, thus a specific site would normally be either very highly
or very lowly methylated. Consequently, when there is increased variability present for a
locus, which means that the values are more widely spread across the range of possible
methylation values, there has to be some shift towards an intermediate mean methylation
value if we want to robustly identify sites with highly variable methylation patterns
compared to those with consistent methylation values across all samples of a group.
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Additionally, mean methylation values lying more in the intermediate regions of the dis-
tribution of DNA methylation data also indicate heterogeneity at another level, namely
at the population of the cells measured. The widely used methylation Beta-value gives
the proportion of methylated probe intensities for a given CpG compared to the overall
intensities measured, that is, unmethylated and methylated intensities together (see for-
mula 3.2 in section 3.2.3), resulting in a percentage of methylation. So, if in one sample
a certain CpG is methylated in exactly half of the cells measured, and unmethylated in
the rest, the result would be a Beta-value of 0.5 for this locus in a given individual. As
heterogeneity observed across cell populations is related to variability across individuals
(see section 1.3), such intermediate methylation values do not only represent high intrain-
dividual methylation heterogeneity but provide a further link to interindivual variability.
The Beta-value however shows heteroscedasticity, as demonstrated by Du et al. (2010),
who found that intermediate Beta-values have increased variability compared to those
close to zero or one, and as can also be seen in supplementary figure SF8. The fig-
ure shows that when methylation Beta-values are ordered according to their variance,
and compared then to the corresponding mean Beta-values, different levels of variability
are not evenly distributed across mean methylation values, again indicating strong het-
eroscedasticity, and showing that the highest variability is present for Beta-values around
0.5. As the distribution of Beta-values is bimodal (see also supplementary figure SF7),
this effect can be especially well observed when splitting the data into two groups of high
and low methylation Beta-values, like in supplementary figure SF9 and SF10.
While on the one hand the observation of increased variability at intermediate methyla-
tion levels makes sense, because of the previously described relationships between vari-
ability within cell populations and variability across individuals, again, the difficulty is
then to determine whether increased variability is observed only because of the average
methylation values lying in regions of the distribution which give higher estimates of
variability per se, and could therefore mainly be caused by the quantification method
used, or because the values are truly more spread out and biologically heterogeneous.
Thus, measurements of variability independent of the mean are desired (the same prob-
lem as has been described in section 4.1.3 for gene expression variability analyses in CLL).
Du et al. (2010) suggested to use M-values instead of Beta-values in order to avoid the
problem of heteroscedasticity. The M-value is the log2 ratio of the intensities of the
methylated probe versus the unmethylated probe (see formula 3.3 in 3.2.3), a measure
that is widely used in gene expression microarray analysis.
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Indeed, when we applied for example Bartlett’s test on data given in Beta-values, it iden-
tified loci as significantly differentially variable where there is actually a more dominant
shift in mean methylation values present, which can be seen when looking at the corre-
sponding M-values. One such example is demonstrated in supplementary figure SF11 in
Annex I. For these reasons DiffVar only works with M-values, better suited for statistical
analyses.
In our comparison of methods, presented in table 4.6, DiffVar and Bartlett’s test showed
quite similar numbers of significantly differentially variable sites in DNA methylation
when using M-values. Around 50% of significant results were in common between these
two methods (data not shown). DiffVar has been described to be generally more robust
to outliers and to outperform the F-test and Bartlett’s test in terms of controlling the
false discovery rate (Phipson & Oshlack, 2014). Interestingly, in our analyses DiffVar
identifies a higher number of significant results compared to Bartlett’s test in some of the
comparisons, possibly due to the increase of statistical power achieved by the enhanced
empirical Bayes approach employed in limma (Ritchie et al., 2015).
Table 4.6: Comparison of results obtained by different methods testing for differential variability. The
numbers show the amount of statistically significant results at a FDR of 0.05. M stands for monocytes,
N for neutrophils, and T for T cells. The arrow indicates hypervariability in the respective cell type
of the corresponding comparison. DiffVar only works with M-values, thus no results are available for
DiffVar with Beta-values.
Beta-values M-values
Bartlett Ansari Bar DiffVar Bartlett Ansari Bar DiffVar
M vs N
N↑ 6308 4 0 NA 872 4 0 942
M↑ 5938 1 0 NA 628 1 0 722
M vs T
T↑ 15546 5 0 NA 168 4 0 139
M↑ 15780 2 0 NA 87 3 0 350
N vs T
T↑ 17538 3 0 NA 94 4 0 185
N↑ 21954 4 0 NA 373 3 0 681
Taking the considerations described in this section together, the framework of limma
combined with DiffVar is the best choice for the complex and interconnected analyses
performed in this study.
4.2.4 DNA Methylation Variability in Normal Blood Cells
As stated in the preceding sections 4.2.2 and 4.2.3, we used DiffVar (Phipson & Oshlack,
2014) embedded in the framework of limma (Smyth, 2005; Ritchie et al., 2015) to analyze
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differential variability across the three cell types. DiffVar calculates the MAD of M-values
and performs the statistical test on these values. We observed that the MAD-value shows
again some degree of heteroscedasticity (see figure 4.9).
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Figure 4.9: Mean M-values versus MAD. CpG-wise MAD-values were calculated. Then the values were
ordered from low to high MAD, grouped together in bins of 300 CpGs, and plotted against the mean
M-value maintaining the ordering by MAD-values, to see if the MAD is evenly distributed across M-
values. Plots of the original data values in comparison with the binned data points, and the same plots
separated into two groups of methylation can be seen in supplementary figures SF12, SF13 and SF14
in Annex I.
A very similar correlation between DNA methylation variability and mean methylation
can be observed when looking at the variance of M-values, as shown in supplementary
figures SF15, SF16 and SF17, and also reported by Heiss & Brenner (2015). Although
the correlation is less pronounced here compared to the observations made on Beta-values
before (see supplementary figures SF8, SF9 and SF10), these relationships between mean
methylation levels and variability measurements are undesirable.
Therefore, we used an additional criterion for defining statistical significance, namely the
variability measurement of Alemu et al. (2014) which we call MV here. The MV-score is a
measurement of variability that corrects for the relationship between mean and variance,
and was originally introduced to measure gene expression variability (see section 3.1.2).
As we work with M-values to measure DNA methylation, similar to gene expression
quantifications (Du et al., 2010), and the method of Alemu et al. (2014) models variance
as a function of the mean using the underlying data distribution, this approach can also
be used here. We only considered results as significant when the Benjamini-Hochberg
corrected p-values (Benjamini & Hochberg, 1995) obtained by DiffVar were smaller than
0.05, and when the absolute MV difference of a CpG between the two groups compared
was bigger than 10% of the whole range of MV-values present in the methylation dataset
(from -2.71 to 3.03), corresponding to an absolute MV difference of 0.57.
65
CHAPTER 4. RESULTS & DISCUSSION
This way, we enforce that a significant result also has a minimum difference between the
two groups in a variability measure that is less dependent on the mean. As can be seen
in figure 4.10, the distribution of the MV-score indeed shows an almost flat profile, where
mean methylation is centered around zero and evenly distributed across different levels
of methylation variability. When again splitting up the data into two groups of high and
low methylation values because of the bimodal distribution, some dependence between
MV-scores and mean methylation appears, especially for extremely low DNA methylation
variability (see supplementary figures SF18, SF19 and SF20), but importantly, also here
the big majority of data points lies within an even region of the profile.
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Figure 4.10: Mean M-values versus MV. CpG-wise MV-scores were calculated. Then the values were
ordered from low to high MV, grouped together in bins of 300 CpGs, and plotted against the mean
M-value maintaining the ordering by MV, to see if the MV is evenly distributed across M-values. Plots
of the original data values in comparison with the binned data points, and the same plots separated into
two groups of methylation can be seen in supplementary figures SF18, SF19 and SF20 in Annex I.
The numbers of significant results get only slightly reduced by applying this additional
threshold in most cases – compare table 4.6 (numbers displayed in parenthesis here again)
and the numbers reported in the following list – indicating that DiffVar performs generally
well in identifying sites with robust differences in variability across the compared groups:
• Hypervariable in monocytes compared to neutrophils: 673 (722)
• Hypervariable in monocytes compared to T cells: 284 (350)
• Hypervariable in neutrophils compared to T cells: 449 (681)
• Hypovariable in monocytes compared to neutrophils: 713 (942)
• Hypovariable in monocytes compared to T cells: 121 (139)
• Hypovariable in neutrophils compared to T cells: 167 (185)
In order to further investigate the obtained results we defined different gene sets of interest
starting from these lists of significant CpGs. First of all, we were interested in CpGs which
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show cell type specific DNA methylation hypervariability, that is, CpGs presenting for
example significantly increased variability in monocytes, but not in the two other cell
types. To do so, we must take the two relevant comparisons into account, the comparison
of monocytes versus neutrophils, and the comparison of monocytes versus T cells. If,
and only if a CpG shows significantly increased variability in monocytes in both of the
comparisons, it is considered as a cell type specific hypervariable locus. That means, we
are looking at the overlaps of the comparisons, represented in figure 4.11.
Figure 4.11: Cell type specific DNA methylation hypervariable sites. Results of the three comparisons of
the analysis of differential variability represented in Venn diagrams showing the overlaps of hypervariable
CpGs between two of the three comparisons in which every cell type is involved.
What can be seen here is that neutrophils show the highest number of cell type specific
hypervariable sites, namely 126, as compared to 97 in monocytes, and 82 in T cells.
Plotting the original methylation values of these sites together with their neighboring
CpGs measured by the microarray, we can see that the procedure used to test for differ-
ential variability here indeed performs very well in identifying loci with strongly increased
variability in one cell type compared to the other two. In figure 4.12 and 4.13 two interest-
ing examples of genes with cell type specific differential methylation variability are shown.
Gene ITGB1BP1 (integrin beta 1 binding protein 1) has two cell type specific hyper-
variable sites in neutrophils, a very strong one in its promoter, and another one in the
3’ untranslated region (UTR). Integrins are essential cell adhesion proteins used to bind
to the extracellular matrix (Alberts et al., 2004; Hynes, 1987). They can regulate their
affinity for extracellular ligands in order to enable cell movement, and they also function
as signal transducers by the induction of intracellular signaling pathways when integrins
are activated by matrix binding (Harburger & Calderwood, 2009; Miranti & Brugge,
2002). Altogether, integrins allow rapid responses to events at the cell surface (Miranti
& Brugge, 2002). Specifically gene ITGB1BP1 has also been shown to play a role in pro-
liferation, differentiation, spreading and migration (Brunner et al., 2011; Fournier et al.,
2005; Bru¨tsch et al., 2010).
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Figure 4.12: Cell type specific DNA methylation hypervariability in gene ITGB1BP1. Every data point
represents the DNA methylation value of the CpG in one sample. The larger data points show the mean
methylation value across individuals within the corresponding group, and are connected by lines. Loci
with significantly increased DNA methylation variability are marked by an arrow in the color of the
corresponding cell type where green stands for monocytes, blue for neutrophils, and yellow for T cells.
HTR2A (serotonin receptor 2A), an important neurotransmitter expressed in many cell
types and playing an important role in a plethora of functions (Williams et al., 2002;
Van de Kar et al., 2001; Tanaka et al., 2008; Yu et al., 2008; Hoyer et al., 2002) is one
of the examples showing highly variable methylation patterns across a whole region of
subsequent CpGs in one of the three cell types. The promoter region of the gene shows
significantly higher methylation variability in T cells than in monocytes or neutrophils.
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Figure 4.13: Cell type specific DNA methylation hypervariability in gene HTR2A. Every data point
represents the DNA methylation value of the CpG in one sample. The larger data points show the mean
methylation value across individuals within the corresponding group, and are connected by lines. Loci
with significantly increased DNA methylation variability are marked by an arrow in the color of the
corresponding cell type where green stands for monocytes, blue for neutrophils, and yellow for T cells.
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Next, we wanted to see if there are hypervariable sites that are shared between two of the
three cell types, which means that we want to find CpGs that have consistent methylation
values in one cell type, but show highly variable methylation patterns in the other two,
or said the other way round, those CpGs that are hypovariable in two of the comparisons
in which the cell type in question is involved. So again, we are looking at the overlaps of
the comparisons, but this time for those with decreased variability, shown in figure 4.14.
Figure 4.14: DNA methylation hypervariable sites shared between two cell types. Results of the three
comparisons of the analysis of differential variability represented in Venn diagrams showing the overlaps
of hypovariable CpGs between two of the three comparisons in which every cell type is involved, thus
showing sites that exhibit hypervariability in the other two cell types.
The biggest overlap is present in the comparison of monocytes and neutrophils versus
T cells, where 106 CpGs share hypervariability in monocytes and neutrophils and are
significantly less or not variable in T cells. This is not unexpected, as monocytes and
neutrophils are both cells of the myeloid lineage, and therefore more similar to each other
than T cells, which belong to the lymphoid compartment.
An example gene showing hypervariable CpGs in monocytes and neutrophils but not
T cells is SOX30 (Sex Determining Region Y Box 30), shown in figure 4.15. It seem to
be four subsequent probes close to the transcription start site of this gene which show
such a pattern of hypervariability in both monocytes and neutrophils, but only one of
them is reaching statistical significance. SOX30 is a transcription factor involved in the
regulation of embryonic development and cell fate determination (Osaki et al., 1999).
Additionally, we were interested in CpGs that are highly variable in all the three cell
types. Such loci cannot be identified by a statistical approach like limma, which works
with contrasts between groups. Therefore, we use another method here. We took the
variability measure used by DiffVar for its statistical test – the MAD-value – of all CpGs
in all three cell types together, ranked the data from high variability to low variability, and
took the minimum value within the top 0.05% genes as the threshold for high variability.
The same was done for the MV-score. This way, we defined a MAD threshold of 1.02,
and a MV threshold of 2.05.
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Figure 4.15: Shared DNA methylation hypervariability in gene SOX30. Every data point represents
the DNA methylation value of the CpG in one sample. The larger data points show the mean methy-
lation value across individuals within the corresponding group, and are connected by lines. Loci with
significantly increased DNA methylation variability are marked by an arrow in the color mix of the two
corresponding cell types (here, monocytes and neutrophils) where green stands for monocytes, blue for
neutrophils, and yellow for T cells.
The two thresholds were then applied to all CpGs (see table 4.7), and those that showed
higher variability than defined by the thresholds in all three groups were then defined as
highly variable across the three cell types.
Table 4.7: Overview of CpGs with hypervariable DNA methylation patterns shared between all three
cell types. The last column shows the number represented as percentage relative to all CpGs analyzed
(n = 423, 089).
Cell type Count Proportion
Monocytes 163 0.04%
Neutrophils 164 0.04%
T cells 143 0.03%
Common to all three cell types 106 0.03%
Altogether, we identified 106 CpGs showing highly variable DNA methylation patterns
across all three cell types. An example of such a gene, DUSP22 (dual specificity protein
phosphatase 22), is shown in figure 4.16.
DUSP22 is an enzyme that activates the JNK (c-JUN N-terminal kinases) signaling
pathway (Chen et al., 2002; Shen et al., 2001) and has been associated with several
diseases such as T-cell lymphoproliferative disorders (Feldman et al., 2011; Csikesz et al.,
2013), Alzheimer’s disease (Sanchez-Mut et al., 2014), and breast cancer (Sekine et al.,
2007), among others.
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Figure 4.16: DNA methylation hypervariability common in all three cell types in gene DUSP22. Every
data point represents the DNA methylation value of the CpG in one sample. The larger data points
show the mean methylation value across individuals within the corresponding group, and are connected
by lines. Loci with significantly increased DNA methylation variability in all three cell types are marked
by a black arrow.
The gene shows highly variable DNA methylation values across many CpGs, in the pro-
moter of the gene as well as in its body. However, such a pattern could also indicate
technical problems with these probes on the microarray, or additional SNPs present in
this region that have not been filtered out. This will have to be further investigated.
Summarizing, we found the following numbers of sites with significantly increased vari-
ability in DNA methylation, shown in figure 4.17 and listed in supplementary table ST6
table s6.html.
Figure 4.17: Summary of CpGs with significantly increased DNA methylation variability.
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4.2.5 Gene Expression Variability in Normal Blood Cells
For gene expression, we performed the same analysis as described for DNA methylation
variability in the preceding section 4.2.4. Also here, the MAD-value used by DiffVar is
not evenly distributed across mean expression levels, and there exists a strong negative
correlation between mean gene expression levels and the MAD, as shown in figure 4.18.
lllllll
llllllllllllllll
l
lllllllllllllll
llllllllllllll
l
llll
llllll
llllll
l
lllllllllll
l
lllll
llllllllll
ll
l
l
llll
l
lll
l
l
l
ll
l
ll
l
l
l
ll
l
l
l
lEx
pr
es
sio
n 
lo
g 
co
un
ts
Monocytes
          Low MAD Intermediate MAD High MAD          
0
2
4
6
8
10
12
14
ll
llllllllllllllllllllllll
lll
lll
llll
l
ll
l
l
lllll
l
l
l
l
l
l
lll
l
lllllllllll
l
l
l
l
ll
l
lll
llllllllll
l
lll
l
l
l
ll
ll
llll
llll
l
l
llll
lll
l
l
lll
lll
l
ll
l
Neutrophils
   Low MAD Intermediate MAD High MAD         
0
2
4
6
8
10
12
14
l
lllllllllllllllll
lllllllllllllllllllllll
lllllllllllll
llllllllllllllllll
l
ll
l
l
llllllllllllllllll
lll
ll
l
l
ll
l
ll
lllll
ll
lllll
l
ll
lll
l
l
T cells
    Low MAD Intermediate MAD High MAD          
0
2
4
6
8
10
12
14
Figure 4.18: Mean expression values versus MAD. Gene-wise MAD-values were calculated. Then the
values were ordered from low to high MAD, grouped together in bins of 100 genes, and plotted against
mean expression log counts maintaining the ordering by MAD-values, to see if the MAD is evenly
distributed across expression levels. Plots of the original data values in comparison with the binned data
points can be seen in supplementary figure SF21 in Annex I.
This negative correlation between mean expression levels and variability is especially
problematic here, as neutrophils exhibit generally lower expression levels than the other
two cell types, which can also be seen in supplementary figure SF22 in Annex I and is
consistent with the literature stating that mature neutrophils – as terminally differenti-
ated cells – show only low transcriptional and translational activities (Geering & Simon,
2011; Amulic et al., 2012; Subrahmanyam et al., 2001; Wong et al., 2013).
Therefore, when not correcting for this dependence, neutrophils would tend to show high
variability in many genes in fact caused by overall lower expression values. We em-
ployed the previously described EV-score of Alemu et al. (2014) again (see section 3.1.2)
and required an absolute EV difference larger than 10% of the total range of EV-values
present in the expression dataset (from -2.46 to 4.41) for statistically significant results,
corresponding to an absolute EV difference of at least 0.69. Furthermore, we only main-
tained genes for which both measurements of variability used (MAD and EV) indicated
an increase of variability for the same group in the two-group comparisons. Again, the
additional EV-threshold was applied to force DV genes to have a minimum difference in
a measure of variability that is less dependent on mean expression levels (see figure 4.19).
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Figure 4.19: Mean expression values versus EV. Gene-wise EV-values were calculated. Then the values
were ordered from low to high EV, grouped together in bins of 100 genes, and plotted against mean
expression log counts maintaining the ordering by EV-values, to see if the EV is evenly distributed
across expression levels. Plots of the original data values in comparison with the binned data points can
be seen in supplementary figure SF23 in Annex I.
The correction for the correlation between mean expression levels and expression vari-
ability did not work perfectly here, as the EV-score still shows some dependence on the
mean expression level – especially in neutrophils, where the mean expression level in
the intermediate range of the EV measurement is lower – but is strongly improved com-
pared to MAD-values, where the generally lower expression levels of neutrophils leads
to a strong increase of MAD-values in this cell type (see supplementary figure SF24 in
Annex I for a comparison of the global distributions of the two variability measures in
the three cell types).
Indeed, when not applying the additional criterion of the minimum EV difference, more
than 5,000 genes were reported to exhibit significantly increased variability in neutrophils
compared to monocytes and T cells (data not shown). After the application of the ad-
ditional threshold, only 544 genes reached significant levels of cell type specific hyper-
variability in this cell type, see figure 4.20. Still, the highest number of cell type specific
hypervariability is observed for neutrophils, and there are also many genes that share
their hypervariable expression patterns between monocytes and neutrophils, similar to
what was observed in the analyses of differential DNA methylation variability described
in section 4.2.4.
The lists of all genes with increased gene expression variability can be found in supple-
mentary table ST7 table s7.html.
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Figure 4.20: Summary of genes with significantly increased gene expression variability.
Plotting the expression values of genes with increased variability we confirmed that the
differences in variability are not driven by decreased expression values in neutrophils.
Some examples are shown in figure 4.21.
l
l
l
l
l
l
ll l
l
l
l
l
l lll
lll
l
ll l
l
lll
l
l
l
ll
l l
ll
l
l
ll
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
lll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
ll lll
l
ll
ll
l
l
lll
l
l
l
ll
ll
l
l
l
l
ll l
l
l
l
ll
l
l
lll
llll
l l
l
l
lll
l
l
l
lll
l
l
ll
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
ll l
l
ll
l
l
l
llll l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll l
l
l
l
l
ll
l
lll llll
llllll lllll l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
lll
l
ll
l
ll
l lll l
l
l
ll
lllll
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l llll l
ll
lll
ll ll lll
ll
l
l
Lo
g 
co
un
ts
NKX3−1
M
on
oc
yt
es
N
eu
tro
ph
ils
T 
ce
lls
0
5
10
15
CD9
M
on
oc
yt
es
N
eu
tro
ph
ils
T 
ce
lls
0
5
10
15
HLA−DQB1
M
on
oc
yt
es
N
eu
tro
ph
ils
T 
ce
lls
0
5
10
15
Figure 4.21: Increased gene expression variability in genes NKX3-1, CD9 and HLA-DQB1. Every data
point represents the expression value of the gene in one sample. The groups in which variability is
increased are marked by an arrow in their corresponding colors.
NKX3-1 (homeobox protein Nkx-3.1) shows increased cell type specific variability in neu-
trophils. The gene is an androgen-regulated transcription factor, predominantly localized
to prostate epithelium with critical functions in prostate development and prostate tumor
suppression (He et al., 1997; Abate-Shen et al., 2008; Asatiani et al., 2005).
The CD9 antigen (motility related protein 1, cell growth inhibiting gene 2 protein, or
tetraspanin 29) shows hypervariable gene expression patterns in both monocytes and
neutrophils, but not in T cells. It is a member of the tetraspanin family, which comprises
cell surface proteins that mediate signal transduction and regulate cell development, dif-
ferentiation, morphology, adhesion, activation, and motility (Hemler, 2005). CD9 is
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furthermore known to form complexes with integrins to modulate cell adhesion and mi-
gration (Hemler, 2005; Berditchevski, 2001).
Also for expression variability, we were interested in genes that share patterns of highly
variable expression values across all three cell types, identified by basically the same
approach as the one used for DNA methylation variability described in the previous
section 4.2.4, except for the fact that here we defined the thresholds of the MAD and
EV-score by looking at the top 10% of all genes, leading to a MAD cutoff of 0.45 and an
EV cutoff of 0.34. The numbers of genes passing these thresholds are shown in table 4.8.
Table 4.8: Overview of genes with hypervariable expression patterns in common in all three cell types.
The last column shows the number represented as percentage relative to all genes analyzed (n = 12, 661).
Cell type Count Proportion
Monocytes 314 2.48%
Neutrophils 703 5.55%
T cells 400 3.16%
Common to all three cell types 66 0.52%
An example of such a gene with hypervariable gene expression values across all three
cell types is HLA-DQB1 (major histocompatibility complex, class II, DQ beta 1), also
shown in figure 4.21. This gene encodes one of the two proteins necessary to form the
DQ cell surface receptor which can present antigens and bind to T cells. Therefore, the
gene is primarily expressed by professional antigen-presenting cells (B cells, macrophages
and dendritic cells), but can also be expressed in all other cell types (Neefjes et al., 2011;
Roche & Furuta, 2015).
Monocytes – as precursors of dentritic cells and macrophages – have functions associated
to the presentation of antigens and possess degradative compartments enriched in ma-
jor histocompatibility complex (MHC) class II molecules (Bunbury et al., 2009; Hornell
et al., 2003). Activated neutrophils are also known to express MHC class II for antigen
presentation and T cell activation (Wright et al., 2010; Amulic et al., 2012). Consistent
with our findings here, MHC class II expression is known to be highly variable in the
human population (Wright et al., 2010; Gosselin et al., 1993). Interestingly, the MHC
class II has also been associated with the above mentioned tetraspanin proteins (Roche
& Furuta, 2015) to which the CD9 gene belongs.
In neutrophils, there seem to exist two groups of expression of HLA-DQB1, causing the
highest intragroup variability among the three cell types. This might suggest that there
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exists an important difference between individuals leading to these two different sub-
groups, such as for example age or sex. However, if this was the case, we would probably
expect to see a similar splitting of expression values by the same individuals in monocytes
and T cells as well, which does not happen. When nevertheless looking at the available
phenotype data for the individuals building the two groups of expression visible in the
plot, no obvious relation between the subgroups and any characteristic of the individuals
for which we have information including age, sex, blood counts, date of the experiment,
etc, can be found, nor can the effect be associated to any kind of further experimental
variables or batch effects.
Such a grouping within cell types leading to significantly increased variability is also
observable in a few other examples of statistically significant genes, and not only in
neutrophils but also in the other two cell types (data not shown). It does however not
seem to consistently happen with the same subgroups of individuals. Instead, the two
groups of expression are formed by different individuals in different cases. This further
indicates that the observation of the two groups of expression present in some genes
is probably not associated with a simple phenotypic or experimental variable directly
related to each individual. However, the described subgrouping pattern does only occur
in few genes and is not a frequent observation among the results.
4.2.6 Sex-Specific Differential Expression in Normal Blood Cells
In the context of the above described observation that in some genes with hypervari-
able expression patterns there are two subgroups of expression levels present within a
cell type (see gene HLA-DQB1 in figure 4.21 for an example), we asked if there might
exist sex-specific gene expression profiles in the three cell types investigated that could
contribute to interindividual variability. Differences in mean expression levels between
particular subgroups within our group of individuals such as males and females could
cause significantly increased intragroup variability. We reasoned that gender could be
the main phenotypic difference present.
It has to be noted that we performed the statistical test applied to assess differential
variability as a paired test (see section 4.2.2), thus differences associated to individuals
like age, gender or blood counts are supposed to be taken into account. However, it is
important to recall that the model works on variability measurements of genes, and not
the actual gene expression values, such that it accounts for effects regarding differences
in variability among the individuals, but possible differences in mean expression levels
corresponding to characteristics of the individuals are not (directly) taken into account.
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So we asked if sex-specific differences in mean gene expression levels could be present
in monocytes, neutrophils and T cells, and if yes, to which extent such differences in
mean expression levels could contribute to the obtained results of highly variable gene
expression patterns in the three cell types.
Using limma’s student’s t-test, we performed now classical differential gene expression
analyses comparing mean expression levels of males and females within each of the three
cell types in order to find out if there are sex-dependent differences in mean gene expres-
sion levels observable.
Surprisingly, we found 620 genes with significantly different mean expression levels be-
tween males and females in neutrophils, while only 80 and seven genes were differentially
expressed between males and females in T cells and monocytes, respectively (see table
4.9 and table ST8 table s8.html for the complete results listing all DE genes). Statistical
significance was determined by Benjamini-Hochberg corrected p-values smaller than 0.05,
and no fold change criterion was applied, as mean expression differences between males
and females are generally small (see also supplementary table ST8 table s8.html).
Table 4.9: Overview of genes differentially expressed between sexes.
Cell type Higher expressed in females Higher expressed in males
Monocytes 6 1
Neutrophils 299 321
T cells 36 44
There are no overlaps between the differentially expressed genes in the three cell types,
except for one gene higher expressed in females in common between monocytes and
T cells (EIF1AXP1 – eukaryotic translation initiation factor 1A, X-linked pseudogene 1),
and one gene higher expressed in males in common between monocytes and T cells
(CCDC144B – coiled-coil domain containing 144B pseudogene).
When looking now at the overlap between the lists of genes with significantly increased
gene expression variability (see section 4.2.5 and supplementary table ST7 table s7.html)
and genes exhibiting significant sex-specific differential expression, a small part of the
genes indeed appears in both (see table 4.10). Thus, a fraction of the results with in-
creased interindividual variability can at least partly be explained by sex-dependent dif-
ferences in gene expression, especially in neutrophils, where the overlap between cell type
specific hypervariable genes and genes with sex-dependent differences in mean expression
is bigger than expected by chance according to hypergeometric tests.
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Table 4.10: Overlaps of differentially variable genes with genes differentially expressed between sexes.
The first column shows the number of genes with significantly differential expression between males
and females in the three cell types. The second column lists the numbers of genes with increased
variability, either cell type specific, shared between two cell types, or in common in all three cell types.
Column ‘Overlap’ shows the number of genes that are contained in both lists, that is, increased gene
expression variability and sex-specific differential expression in the corresponding cell type. Column
‘Proportion’ contains the percentage of genes with sex-specific differential expression that are present in
the corresponding list of increased gene expression variability, and the last column shows the p-values of
hypergeometric tests indicating if the overlaps are bigger than expected by chance.
Increased variability Overlap Proportion p-value
S
ex
-s
p
ec
ifi
c
ge
n
e
ex
p
re
ss
io
n
N
eu
t
(6
20
) Neutrophils 544 53 9.74% 0.0000
Neutrophils & monocytes 340 17 5.00% 0.1384
Neutrophils & T cells 76 4 5.26% 0.3168
Common 66 1 1.52% 0.9196
M
on
o
(7
) Monocytes 58 0 0.00% 1.0000
Monocytes & neutrophils 340 0 0.00% 1.0000
Monocytes & T cells 30 0 0.00% 1.0000
Common 66 0 0.00% 1.0000
T
ce
ll
s
(8
0) T cells 131 4 3.05% 0.0037
T cells & monocytes 30 1 3.33% 0.1352
T cells & neutrophils 76 0 0.00% 1.0000
Common 66 0 0.00% 1.0000
To further investigate the interesting result of 620 genes exhibiting differential expression
between males and females in neutrophils, we tested for functional enrichments within
the 299 genes higher expressed in females and the 321 genes higher expressed in males.
Interestingly, genes that show higher expression levels in neutrophils derived from females
are enriched for functions related to the immune system, while genes higher expressed in
males seem to be enriched for cellular compartments like the nuclear envelope, membrane-
bound organelles, and so on. The complete results of the functional enrichment analyses
can be seen in supplementary table ST9 table s9.html.
The enrichment of immune system related functions in genes that are higher expressed
in females is not unexpected, as the longer life-span of females has been associated to
differences in the immune system (Berghella et al., 2012; Hirokawa et al., 2013), it is
long known that females show elevated immune responses compared to men (Grossman,
1985; Schuurs & Verheul, 1990; Ansar Ahmed et al., 1985; Markle & Fish, 2014; Scot-
land et al., 2011), and many auto-immune diseases have a higher incidence in females as
well (Fairweather et al., 2008; Ansar Ahmed et al., 1985; Fish, 2008; Markle & Fish, 2014).
The association of genes that are higher expressed in males with cellular compartments,
especially the nucleus with further enriched terms like “nuclear part” and “nuclear en-
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velope” is also very interesting, as there exist differences in the polymorph nuclei of
neutrophils derived from males and females (Davidson & Smith, 1954). In females, the
neutrophil nucleus has an additional chromatin nodule, separated off from the main nu-
clear lobes. This additional structure is called neutrophil drumstick. Also sex-dependent
differences in the formation of NETs have been reported (Tillack et al., 2013), among
other gender-specific differences in neutrophils (Aomatsu et al., 2013; Molloy et al., 2013;
Spitzer & Zhang, 1996).
Some examples of the genes that are higher expressed in females and contribute to the en-
richment of immune system processes are CSF1 (colony stimulating factor 1), a cytokine
that plays an essential role in survival, proliferation and differentiation of hematopoi-
etic precursor cells (Stanley et al., 1997), IL-27 (Interleukin-27), a cytokine with pro-
and anti-inflammatory properties that can regulate important functions in T cells (Lucas
et al., 2003; Pflanz et al., 2002; Neufert et al., 2007), and CX3CL1 (chemokine C-X3-C
motif ligand, also known as fractalkine), which has been shown to be chemotactic and
plays a role in leukocyte adhesion and migration (Imai et al., 1997; Bazan et al., 1997).
Genes that contribute to the enrichment of the nuclear envelope cellular compartment
in males are for example several nucleoporins (NUP37, NUP155, NUP188), a family of
proteins that build the nuclear pore complex (NPC), which is a structure that extends
across the nuclear envelope and allows the flow of macromolecules between the nucleus
and the cytoplasm (Doye & Hurt, 1997; Corbett & Silver, 1997), AHCTF1 (AT hook
containing transcription factor 1), a gene required for the assembly of the NPC and cell
division (Rasala et al., 2006; Bilokapic & Schwartz, 2012), CSE1L (chromosome segrega-
tion 1-like protein), an export receptor that also plays important roles in cell proliferation
and apoptosis (Brinkmann et al., 1995; Kutay et al., 1997; Behrens et al., 2003), and LBR
(lamin B receptor), which is localized in the inner membrane of the nuclear envelope and
anchors the lamina and the heterochromatin to the membrane (Pyrpasopoulou et al.,
1996; Ye & Worman, 1994).
For three of the genes differentially expressed between males and females in neutrophils
we also found statistically significant differences in their DNA methylation patterns. The
most striking example is the gene NSD1 (nuclear receptor binding set domain protein 1),
which is higher expressed in males and shows three CpGs in its promoter which are sig-
nificantly hypomethylated in males as well (data not shown). Interestingly, NSD1 has
been reported to act as a transcriptional regulator and to enhance androgen receptor
transactivation (Huang et al., 1998). It is an autoregulatory H3 lysine-36 and H4 lyine-
20 specific histone methyltransferase (Qiao et al., 2011; Wang et al., 2007; Lucio-Eterovic
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et al., 2010), and mutations of the gene cause the Sotos syndrome (Kurotaki et al., 2002;
Douglas et al., 2003) and Weaver syndrome (Douglas et al., 2003), both of which are
childhood overgrowth syndromes. Furthermore, NSD1 has been associated with acute
myeloid leukemia (AML) and an adult form of the myelodysplastic syndrome (Jaju et al.,
2001; Wang et al., 2007; Hollink et al., 2011; La Starza et al., 2004).
It is important to note here that the observed gender-specific differences could be con-
founded by hormonal alterations. In our dataset, there is a slight bias onto older indi-
viduals present in females, and most of the women included in the dataset are probably
post-menopausal.
Finally, we asked if the striking differential expression between males and females in
neutrophils is indeed completely neutrophil-specific. That is, if the sex-specific dif-
ferential expression observed in neutrophils does only occur within neutrophils, or if
it is also present in other cell types, but less strong and therefore below statistical
significance. To this aim, we took the expression differences between males and fe-
males in monocytes as “baseline” in the model testing for differential expression be-
tween males and females in neutrophils. The model works by the definition of a “con-
trast of contrasts”, comparing the differential expression observed in one contrast ver-
sus the differential expression observed in the other, with the following function call:
makeContrasts(cont=(female neutrophils-male neutrophils)-(female monocytes-
male monocytes)).
This way, the differential expression between females and males in monocytes serves as a
kind of reference of expression differences to see if the differences that exist between fe-
males and males in neutrophils are significantly different from those that may be present
in monocytes. If such differences between males and females are – at least partly – also
present in monocytes, this approach removes such results and only reports sex-specific dif-
ferential expression for genes that are truly neutrophil-specific as compared to monocytes,
with the advantage of not having to rely on hard cut-offs defining statistical significance
for the separate gender-comparisons of monocytes and neutrophils.
Using this technique tailored to answer the question of neutrophil-specificity, we found
only 25 genes with higher expression levels in males (of which 23 are in common with
the previously obtained genes) and 23 genes with higher expression in females (of which
21 are in common with previous results) in neutrophils in the current – still small –
dataset, too few to perform meaningful functional enrichment analyses. Concluding, a
part of the gender-specific differential expression observed in neutrophils seems to also be
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present in monocytes, but less strongly pronounced, and therefore not reaching statistical
significance in a classical approach testing for differential expression between males and
females within each cell type separately.
4.2.7 Relationship Between DNA Methylation Variability and
Gene Expression
Finally, we investigated the effect of DNA methylation variability on gene expression pat-
terns using several different approaches. First of all, to get a visual impression of if there
is any global tendency present, we plotted the mean expression values of each cell type
versus another, and marked genes with significantly increased variability in DNA methy-
lation. No obvious relationship between the two could be detected, genes with increased
DNA methylation variability seem to be randomly distributed (see supplementary figure
SF25 in Annex I).
The same happened when plotting gene expression variability represented by the EV-
score. No global pattern of a relation between DNA methylation variability and expres-
sion variability could be observed (see supplementary figure SF26 in Annex I), and also
not for other measurements of gene expression variability such as the CV for example
(data not shown).
Next, we plotted the mean expression level and EV-score of genes with significantly dif-
ferentially variable CpGs for the cell type in which the increased variability had been
observed, as well as the other two cell types, in order to compare them. To this aim we
used boxplots, and again, as can be seen in supplementary figure SF27 in Annex I, no con-
sistent cell type specific or general trends are present. This might be the case because the
number of genes contained in some of the boxplots is too small to produce robust patterns.
When calculating the overlaps between genes that show significantly increased DNA
methylation variability in either their promoters or gene bodies and gene expression vari-
ability for the previously obtained lists of interesting genes (that is, genes with cell type
specific variability, genes that share variability between two of the three cell types, and
genes that show hypervariability in all three cell types), no significant overlaps could be
found (see table 4.11). This result indicates that in general DNA methylation variability
in a gene’s promoter or body does not seem to lead to a direct and straight-forward
increase of variability in its expression.
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Table 4.11: Overlaps of highly variable genes in DNA methylation and gene expression. Column ‘Var
genes methyl’ lists the number of genes with significantly increased variability in their DNA methyla-
tion, column ‘Var genes exprs’ lists the number of genes with significantly increased variability in their
expression, column ‘Overlap’ represents the overlap between the two, and the last column contains the
p-values of hypergeometric tests, indicating if the overlap is bigger than expected by chance.
Var genes methyl Var genes exprs Overlap p-value
P
ro
m
o
te
r
m
et
h
y
la
ti
o
n Monocytes 39 58 0 1.0000
Neutrophils 26 544 0 1.0000
T cells 18 131 0 1.0000
Monocytes & neutrophils 19 340 0 1.0000
Monocytes & T cells 5 30 0 1.0000
Neutrophils & T cells 0 76 0 1.0000
In all three cell types 19 66 0 1.0000
B
o
d
y
m
et
h
y
la
ti
on
Monocytes 30 58 0 1.0000
Neutrophils 59 544 2 0.8136
T cells 31 131 2 0.0558
Monocytes & neutrophils 77 340 2 0.7126
Monocytes & T cells 8 30 0 1.0000
Neutrophils & T cells 1 76 0 1.0000
In all three cell types 61 66 1 0.3176
This observation is further confirmed by the fact that when we took the DNA methyla-
tion measurements of genes with increased interindividual methylation variability of every
single individual and tried to correlate them with the corresponding expression measure-
ments in these individuals, we often did not see any relation between DNA methylation
and gene expression levels (data not shown). Similar observations have been made by
Lam et al. (2012), who could not find an obvious association between DNA methylation
variability and gene expression in their study of PBMCs across 92 individuals.
However, when analyzing the global correlation between DNA methylation variability and
gene expression by plotting them against each other using a binning approach, interesting
relationships between DNA methylation variability and gene expression patterns can be
revealed, see figure 4.22. For the binning applied in these plots we calculated the median
DNA methylation variability value per ensembl gene separately for gene promoters and
gene bodies, ordered the genes by their corresponding DNA methylation variability val-
ues, binned every subsequent 100 genes together by calculating their mean expression log
counts or mean expression variability, and plotted them ordered by their DNA methyla-
tion variability from low to high on the x-axis versus the corresponding variable of interest
on the y-axis, either mean expression levels or expression variability measurements.
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Figure 4.22: Global relationship between promoter methylation variability and gene expression. Gene-
wise MV-values were calculated. Then the values were ordered from low to high MV, grouped together
in bins of 100 genes, and plotted against the mean expression values (top row) or against the EV (bottom
row), maintaining the ordering by MV-values. Plots of the original data values in comparison with the
binned data points can be found in supplementary figure SF28 in Annex I.
This binning strategy was adopted to reduce the complexity of the data, in order to be
able do detect and visualize tendencies that can be difficult to reveal when dealing with
huge amounts of individual data points, as is the case here.
Indeed, when the genes were divided in classes of different levels of DNA methylation
variability in their promoters as described above, a very consistent pattern emerged (see
top row of figure 4.22). Genes showing very low DNA methylation variability in their
promoters seem to be lowly expressed, for increasing DNA methylation variability the ex-
pression levels become higher and then lower again in a curve, and genes with extremely
variable DNA methylation patterns in their promoters seem to be lowly expressed again.
Strikingly, a very similar pattern can be observed for all three cell types.
When looking again at the same classes of genes – determined by the level of DNA methy-
lation variability present in their promoters as described above – but now considering the
EV-score instead of mean expression levels, a kind of inverse or mirrored pattern can be
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observed, where higher expression variability is present for both very low and very high
DNA methylation variability (bottom row of figure 4.22).
At first sight, the trend of an inverse pattern between mean expression levels (top row
of figure 4.22) and expression variability (bottom row of figure 4.22) might lead again
to the negative correlation between mean expression and expression variability. How-
ever, the EV-score is a measurement of variability that is relatively independent from
mean expression levels, and the relationships that are observed when looking at figure
4.23 – which shows the same analysis for gene body methylation – do not exhibit such
a mirrored image for mean expression and expression variability. This indicates that the
present patterns of correlation might indeed be driven by DNA methylation variability.
For gene body methylation variability the corresponding change in mean expression or
expression variability does not seem to be as strong as for promoters, and the pattern is
a more linear one (see figure 4.23).
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Figure 4.23: Global relationship between gene body methylation variability and gene expression. Gene-
wise MV-values were calculated. Then the values were ordered from low to high MV, grouped together
in bins of 100 genes, and plotted against the mean expression values (top row) or against the EV (bottom
row), maintaining the ordering by MV-values. Plots of the original data values in comparison with the
binned data points can be found in supplementary figure SF29 in Annex I.
84
CHAPTER 4. RESULTS & DISCUSSION
Here, both increased mean expression levels and increased expression variability are ob-
served with increasing DNA methylation variability. Especially interesting are the “out-
liers”, at the very extremes of the plot, showing that very high DNA methylation vari-
ability in gene bodies tends to correspond to very high expression variability as well. The
same seems to happen for gene promoters, where the very last data point containing the
100 genes with highest variability in promoter methylation also shows the highest level
of gene expression variability (see previous figure 4.22).
4.2.8 Interpretation and Further Discussion
The second part of this thesis dealing with the novel field of DNA methylation and gene
expression variability in normal blood cells presented here aimed to describe and discuss
the methodological framework established to perform well-defined, robust and compara-
ble analyses across different biological data types and distinct research questions.
We developed a new integrated approach combining statistical methods embedded in the
well-established framework of limma (Smyth, 2005; Ritchie et al., 2015) with additional
measurements of variability taking the mean-variance relationship into account which is
suitable for the analysis of differences in mean and differences in variability at the level
of both DNA methylation and gene expression, and provides a sound basis for the study
of their interrelationships.
First results showed that our approach works very well in the identification of genes with
hypervariable DNA methylation and gene expression patterns, as described in section
4.2.4 and 4.2.5 and demonstrated by several examples.
Overall, our analyses on the initial dataset revealed that neutrophils exhibit both in-
creased DNA methylation and gene expression variability compared to monocytes and
T cells. This observation could possibly relate to the fact that neutrophils are the first
cells to migrate to sites of inflammation (Hoffman et al., 2012; Mo´csai, 2013; Amulic
et al., 2012; Kolaczkowska & Kubes, 2013; Bardoel et al., 2014), as stochastic epigenetic
and transcriptional fluctuations are known to be essential to enable rapid reactions to
changes in the environment, previously described in the introductory section 1.3.2 of this
thesis. The observation that especially genes with important functions in intracellular
signalling, cell adhesion, and motility show increased variability in neutrophils – as has
also been demonstrated for some specific examples in section 4.2.4 and 4.2.5 – reinforces
this hypothesis.
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In recent years it has furthermore become increasingly appreciated that neutrophils are
much more plastic than previously thought (Amulic et al., 2012; Beyrau et al., 2012;
Mo´csai, 2013; Takashima & Yao, 2015). It is now well-established that neutrophils play
a diverse role in both innate immune defense and as effector cells of adaptive immu-
nity, and that they use multiple highly sophisticated mechanisms to locate and kill
pathogens by phagocytosis, degranulation and NETosis (Amulic et al., 2012; Mo´csai,
2013; Kolaczkowska & Kubes, 2013; Bardoel et al., 2014). The highly variable DNA
methylation and gene expression patterns of neutrophils might relate to their immense
functional diversity.
Moreover, neutrophil heterogeneity from individual to individual has been previously re-
ported for different aspects of neutrophil biology (Seligmann et al., 1981; Goldschmeding
et al., 1992; Smith, 1994; Galli et al., 2011), and there also exists the hypothesis that dif-
ferent functional subsets of neutrophils with distinct characteristics and biological roles
might exist (Kolaczkowska & Kubes, 2013; Gallin, 1984). Differing neutrophil activa-
tion rates across individuals could also play a role in the observation of increased DNA
methylation and gene expression variability in neutrophils. Additionally, it has to be
noted that experimental purification procedures could have led to neutrophil activation
in vitro. The gene expression patterns of neutrophils are known to change dramatically
upon priming and activation (Subrahmanyam et al., 2001; Wright et al., 2010).
Another potential source of the observed gene expression hypervariability in neutrophils
related to the specific molecular biology of this cell type might be intron retention, as it
has been shown that neutrophil messenger RNAs are able to retain their introns (Wong
et al., 2013). The amount of retained introns increases during neutrophil differentiation,
leading to strongly reduced protein levels in mature neutrophils due to intron retention
dependent mechanisms of downregulation and premature stop codons (Wong et al., 2013).
The analyses presented in this work were performed on read counts per gene, not distin-
guishing between introns and exons, which could have an impact on variability observed
at the level of genes. New alternative quantification techniques of RNAseq data will allow
to address this hypothesis.
Beside these molecular biological differences that can potentially explain the increased
variability present in neutrophils, also environmental factors could play a role here, as
described in section 1.2 and 1.3.2. For example, circadian rhythms are known to have
an impact on cells of the immune system (Born et al., 1997; Scheiermann et al., 2012;
Me´ndez-Ferrer et al., 2008; Keller et al., 2009), especially also neutrophils (Wirths et al.,
2014; Jilma et al., 1999; Abrahamsen et al., 1993; Smith, 1994; Casanova-Acebes et al.,
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2013). Additionally, seasonal changes could influence DNA methylation and gene expres-
sion variation (Dopico et al., 2015; Dowell, 2001), as the samples analyzed in this work
have been collected over a time span of six months.
It has further been shown that immune cells, including neutrophils, are influenced by
diet, physical activity and psychological stress to name a few examples (Smith, 1994;
Neubauer et al., 2013; Cooper et al., 2007). All these environmental factors are also
known to be associated with DNA methylation and gene expression changes (Horsburgh
et al., 2015; Voisin et al., 2015; Klengel et al., 2014; Powell et al., 2013; Jump & Clarke,
1999; Anderson et al., 2012; Radom-Aizik et al., 2008).
Summarizing, with the here developed methodology we were able to for the first time
analyze interindividual DNA methylation and gene expression variability of human mono-
cytes, neutrophils and T cells using matched samples of a sufficient number of individuals
to be able to robustly quantify variability. The relation between interindividual hetero-
geneity and cell to cell variability introduced in the first chapter of this work allows us
to link the results obtained from these analyses to the concepts of biological variability
described in section 1.3.2, especially the possible relation between the observation of in-
creased variability in neutrophils and the specific requirement of these cells to rapidly
react to new or changing conditions such as the appearance of pathogens or ongoing in-
flammatory processes.
Notwithstanding, additional experimental validation and especially single cell sequencing
data will be necessary to achieve deeper insights to verify these hypotheses and further
investigate the biological implication of DNA methylation and gene expression hetero-
geneity in different cell types of the human immune system.
4.2.9 Outlook
As described in section 3.2.1, the BLUEPRINT dataset used here to develop the method-
ology for the diverse types of analyses performed in this project will soon be extended to
200 individuals, and will additionally also include WGS and chromatin data of the same
individuals (see figure 3.1).
These data will allow us to address an important remaining aspect of this work, namely to
determine to which extent the observed DNA methylation and gene expression variability
can be related to genetic variation, and to separate such genetically driven variability well
from heterogeneity potentially arising due to environmental factors, where especially epi-
genetic changes are thought to play an important role, and intrinsic stochastic variation,
87
CHAPTER 4. RESULTS & DISCUSSION
as introduced in section 1.2, 1.3.1 and 1.3.2. Some authors reported that genetic hetero-
geneity only seemed to explain expression variability to a small extent in their studies
(Li et al., 2010; Battle et al., 2014), and also copy number variations (CNVs) could not
be directly associated to increased levels of gene expression variability (Li et al., 2010;
Raser & O’Shea, 2005; Alemu et al., 2014).
Others however have linked gene expression variation with responsiveness to mutation
(Lehner & Kaneko, 2011), and recent genome-wide quantitative trait loci mapping has
revealed widespread associations of genetic variation with gene expression (Morley et al.,
2004; Cheung et al., 2005; Go¨ring et al., 2007; Stranger et al., 2007; Cheung & Spielman,
2009; Dimas et al., 2009; Albert & Kruglyak, 2015; Naranbhai et al., 2015; GTEx Con-
sortium, 2015; Rivas et al., 2015) and DNA methylation (Gibbs et al., 2010; Bell et al.,
2011; Heyn et al., 2013; Smith et al., 2014; Wagner et al., 2014; Roadmap Epigenomics
Consortium, 2015).
Furthermore, the larger dataset that will soon be available from the BLUEPRINT con-
sortium will provide the opportunity to directly address the hypotheses generated by the
analyses of the pilot dataset presented in this work. The increased statistical power of the
new data will for example help to further investigate the interesting result of sex-specific
gene expression in neutrophils, for which only a small number of samples derived from
females is available in the current dataset of 48 individuals.
The larger and more complete dataset will also allow to further interrogate the consis-
tency of the here identified patterns of DNA methylation and gene expression variability
and their interrelationships, as well as a detailed characterization thereof, for example in
terms of genomic features such as CpG density, or in terms of transcription factor binding
sites, which have been reported to be associated with DNA methylation variability in a
study investigating mouse stem cells (Lienert et al., 2011). The addition of chromatin
information to the new dataset will provide important further insight here, as specific
histone marks and chromatin states have been suggested to play a role in transcriptional
variability as well (Busslinger & Tarakhovsky, 2014; Voss & Hager, 2014; Kaern et al.,
2005; Choi & Kim, 2009; Pujadas & Feinberg, 2012).
Detailed analyses of the specific biological functions of genes exhibiting hypervariable
DNA methylation or gene expression patterns and functional assays to analyze for ex-
ample neutrophil degranulation, respiratory burst, and adhesion in response to multiple
physiological stimuli will further help to achieve a deeper understanding of epigenetic
and transcriptional variability in the here investigated immune cells, and particularly in
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neutrophils, for which we obtained many interesting results in the preliminary analysis
of the pilot data to be followed up with the complete dataset and in further experiments.
Concluding, the present study of heterogeneity in normal human blood cells opens new
doors for future research and provides grounds for additional experimental validation,
which will enable a better understanding of the biological basis behind large phenotypic
plasticity present in immune cells, and which will have the potential to empower the devel-
opment of strategies to modulate variability in hematopoietic and immunological diseases.
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Chapter 5
Conclusions
1. Analysis of Variability in Chronic Lymphocytic Leukemia
1.1 The more aggressive type of CLL, U-CLL, is characterized by higher interindi-
vidual gene expression variability.
1.2 Genes with increased gene expression variability in U-CLL are enriched for the
following functions highly relevant to the disease:
(a) Intercellular communication and signaling, playing a key role in CLL through
the B cell receptor.
(b) Differentiation and development, as well as cell death and apoptosis, which
are basic components of leukemogenesis and disease progression.
(c) Cell cycle and proliferation, reinforcing the link between increased gene ex-
pression variability and a more progressive disease.
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2. Analysis of Variability in Normal Blood Cells
2.1 The integrated approach combining the statistical framework limma, DiffVar,
and a variability measurement that corrects for the mean-variance relationship
developed here is well suited for the analysis and comparison of interindividual
differential variability in DNA methylation and gene expression datasets.
2.2 Neutrophils show increased variability in their DNA methylation patterns com-
pared to monocytes and T cells.
2.3 Neutrophils show strongly increased variability in their gene expression patterns
compared to monocytes and T cells.
2.4 Neutrophils exhibit more or stronger transcriptional differences between sexes
than monocytes and T cells, which partly contribute to the observed increased
gene expression variability in this cell type.
2.5 There exist interesting patterns of correlation between DNA methylation variabil-
ity and gene expression that are consistent across all three cell types analyzed.
3. General Conclusion
“Noise” matters. Epigenetic and transcriptional variability represent valuable informa-
tion in the study of both physiological and pathological conditions. The here obtained
results point to a crucial role of variability at the level of DNA methylation and gene
expression in leukemia and the human immune system, which can be interpreted in the
light of the proposed importance of intrinsic and extrinsic variability present in every
biological process.
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Conclusiones
1. Ana´lisis de la Variabilidad en la Leucemia Linfoc´ıtica Cro´nica
1.1 El tipo ma´s agresivo de leucemia linfoc´ıtica cro´nica, U-CLL, se caracteriza por
una mayor variabilidad de la expresio´n ge´nica interindividual.
1.2 Los genes con una mayor variabilidad en la expresio´n ge´nica en U-CLL esta´n
enriquecidos en las siguientes funciones de gran relevancia en la enfermedad:
(a) Comunicacio´n y sen˜alizacio´n intercelular, jugando un papel clave en la leucemia
linfoc´ıtica cro´nica a trave´s del receptor de ce´lulas B.
(b) Diferenciacio´n y desarrollo, as´ı como muerte celular y apoptosis, las cuales
son componentes ba´sicos de la leucemoge´nesis y progresio´n de la enfermedad.
(c) Ciclo celular y proliferacio´n, reforzando el v´ınculo entre el aumento de la
variabilidad de la expresio´n ge´nica y una enfermedad ma´s progresiva.
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2. Ana´lisis de la Variabilidad en Ce´lulas Sangu´ıneas Normales
2.1 La metodolog´ıa integrada que combina el marco estad´ıstico de limma, DiffVar,
y una medida de la variabilidad que corrige por la relacio´n entre la media y la
varianza desarrollada en este trabajo, es ido´nea para el ana´lisis y comparacio´n de
la variabilidad diferencial interindividual en conjuntos de datos de metilacio´n del
ADN y expresio´n de genes.
2.2 Los neutro´filos muestran una mayor variabilidad en sus patrones de metilacio´n
del ADN en comparacio´n con monocitos y ce´lulas T.
2.3 Los neutro´filos muestran un aumento fuerte de la variabilidad en sus patrones de
expresio´n de genes en comparacio´n con monocitos y ce´lulas T.
2.4 Hay mayores diferencias transcripcionales entre personas de distintos sexos en
neutro´filos que en monocitos y ce´lulas T. Estas diferencias contribuyen parcial-
mente al aumento de la variabilidad de expresio´n ge´nica en este tipo celular.
2.5 Existen patrones de correlacio´n interesantes entre la variabilidad de la metilacio´n
del ADN y la expresio´n de genes que son consistentes en los tres tipos celulares
analizados.
3. General Conclusion
El “ruido” es importante. La variabilidad epigene´tica y transcripcional representa infor-
macio´n valiosa, tanto en el estudio de condiciones fisiolo´gicas como patolo´gicas. Los resul-
tados obtenidos en este trabajo indican que la variabilidad desempen˜a un papel crucial a
nivel de la metilacio´n del ADN y la expresio´n ge´nica en la leucemia y en el sistema inmune
humano. Estos resultados pueden ser interpretados a la luz de la propuesta importancia
de la variabilidad intr´ınseca y extr´ınseca presente en todos los procesos biolo´gicos.
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Supplementary Material

Gene Expression Variability in CLL
Supplementary Figures
Figure SF1: Scatterplots of CV and EV distributions and their correlation with mean expression. Darker
colors indicate an increased density of data points in the corresponding region of the plot. Top row: CV
versus mean expression across all CLL samples, and across only M-CLL and U-CLL samples respectively.
Bottom row: The same for the EV.
Figure taken from Ecker et al. (2015).
145
Figure SF2: Correlation of EV and CV in the data of the ICGC and Fabris. Lighter colors indicate
higher densities of data points in the corresponding regions of the plot. Left panel: Scatterplot of EV
versus CV using the ICGC dataset. Right panel: Scatterplot of EV versus CV using the Fabris dataset.
Figure taken from Ecker et al. (2015).
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Figure SF3: Gene expression variability comparison of U-CLL and M-CLL in the datasets of Fabris and
Haslinger. Lighter colors indicate higher densities of data points in the corresponding regions of the
plot. Genes with statistically significant p-values at an FDR of 5% are highlighted. The gray dashed
line represents the identity line. Left panel: Scatterplot of CV across patients in the two disease sub-
types. Genes with statistically significant differential variability according to the F-test are highlighted.
Middle panel: Scatterplot of EV across patients in the two disease subtypes. Genes with statistically
significant differential variability according to the F-test are highlighted again. Right panel: Scatterplot
of mean expression levels across patients in the two disease subtypes. Genes with statistically significant
differential expression are highlighted. Top row: Data of Fabris. Bottom row: Data of Haslinger.
Figure taken from Ecker et al. (2015).
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Figure SF4: Correlation of variability measurements between the ICGC data and the dataset of Fabris.
Scatterplots comparing the two datasets. Lighter colors indicate higher densities of data points in
the corresponding regions of the plot. The gray line represents the identity line, the blue dashed line
represents the fitted regression line. Upper left panel: CV of M-CLL in Fabris versus CV of M-CLL in
the ICGC data. Upper right panel: CV of U-CLL in Fabris versus CV of U-CLL in the ICGC data.
Lower left panel: CV difference (CVM-CLL−CVU-CLL) in Fabris versus CV difference in the ICGC data.
Lower right panel: SD across all CLL samples in Fabris versus SD in the ICGC data.
Figure taken from Ecker et al. (2015).
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Figure SF5: Correlation of EV difference and CV difference in the ICGC data and the dataset of Fabris.
EV difference = EVM-CLL−EVU-CLL and CV difference = CVM-CLL−CVU-CLL. Lighter colors indicate
higher densities of data points in the corresponding regions of the plot. The blue dashed line represents
the fitted regression line. Left panel: Scatterplot of EV difference versus CV difference using the ICGC
dataset. Right panel: Scatterplot of EV difference versus CV difference using the Fabris data.
Figure taken from Ecker et al. (2015).
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Figure SF6: Beanplots comparing the methylation profiles of M-CLL and U-CLL of the top 500 genes
with increased variability in U-CLL. Methylation measurements are given in beta values. Top row:
Promoter methylation. Bottom row: Gene body methylation. Left panel: Differential variability based
on CV differences. Right panel: Differential variability based on EV differences.
Figure taken from Ecker et al. (2015).
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Variability in Normal Blood Cells
Supplementary Figures
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Figure SF7: Distribution of Beta-values and M-values in the three cell types. Top row: Beta-value
distribution in monocytes, neutrophils and T cells. Bottom row: M-value distribution in monocytes,
neutrophils and T cells.
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Figure SF8: Mean Beta-values versus variance of Beta-values. Top row: CpG-wise variances of Beta-
values were calculated. Then the values were ordered from low to high variance, grouped together in
bins of 300 CpGs, and plotted against the mean Beta-value maintaining the ordering by variance, to see
if variance is evenly distributed across Beta-values. Middle row: Scatterplots of the original data values,
including the binned data points from the plots in the first row (filled circles). Bottom row: Scatterplots
of the original data values, with a lowess regression line. When calculating median Beta-values instead
of mean Beta-values the observed patterns are almost perfectly the same (not shown).
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Figure SF9: Mean Beta-values versus variance of Beta-values in high Beta-values (≥ 0.5). Top row: CpG-
wise variances of Beta-values were calculated. Then the values were ordered from low to high variance,
grouped together in bins of 300 CpGs, and plotted against the mean Beta-value maintaining the ordering
by variance, to see if variance is evenly distributed across Beta-values. Middle row: Scatterplots of the
original data values, including the binned data points from the plots in the first row (filled circles).
Bottom row: Scatterplots of the original data values, with a lowess regression line. When calculating
median Beta-values instead of mean Beta-values the observed patterns are almost perfectly the same
(not shown).
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Figure SF10: Mean Beta-values versus variance of Beta-values in low Beta-values (< 0.5). Top row: CpG-
wise variances of Beta-values were calculated. Then the values were ordered from low to high variance,
grouped together in bins of 300 CpGs, and plotted against the mean Beta-value maintaining the ordering
by variance, to see if variance is evenly distributed across Beta-values. Middle row: Scatterplots of the
original data values, including the binned data points from the plots in the first row (filled circles).
Bottom row: Scatterplots of the original data values, with a lowess regression line. When calculating
median Beta-values instead of mean Beta-values the observed patterns are almost perfectly the same
(not shown).
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Figure SF11: Beta-values and M-values of probe cg07804973. Every data point represents the methyla-
tion value of one individual. The bigger data points correspond to the mean methylation value. Methy-
lation values of this probe in neutrophils seem to be more spread out and therefore more variable in
neutrophils when looking at Beta-values, but not when using M-values, which indicate that the locus is
less methylated in neutrophils, but not showing much higher methylation variability than monocytes or
T cells.
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Figure SF12: Mean M-values versus MAD of M-values. Top row: CpG-wise MAD-values of M-values
were calculated. Then the values were ordered from low to high MAD, grouped together in bins of 300
CpGs, and plotted against the mean M-value maintaining the ordering by MAD, to see if variability
in terms of MAD-values is evenly distributed across M-values. Middle row: Scatterplots of the original
data values, including the binned data points from the plots in the first row (filled circles). Bottom row:
Scatterplots of the original data values, with a lowess regression line.
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Figure SF13: Mean M-values versus MAD of M-values in positive M-values (≥ 0). Top row: CpG-
wise MAD-values of M-values were calculated. Then the values were ordered from low to high MAD,
grouped together in bins of 300 CpGs, and plotted against the mean M-value maintaining the ordering
by MAD, to see if variability in terms of MAD-values is evenly distributed across M-values. Middle row:
Scatterplots of the original data values, including the binned data points from the plots in the first row
(filled circles). Bottom row: Scatterplots of the original data values, with a lowess regression line.
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Figure SF14: Mean M-values versus MAD of M-values in negative M-values (< 0). Top row: CpG-
wise MAD-values of M-values were calculated. Then the values were ordered from low to high MAD,
grouped together in bins of 300 CpGs, and plotted against the mean M-value maintaining the ordering
by MAD, to see if variability in terms of MAD-values is evenly distributed across M-values. Middle row:
Scatterplots of the original data values, including the binned data points from the plots in the first row
(filled circles). Bottom row: Scatterplots of the original data values, with a lowess regression line.
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Figure SF15: Mean M-values versus variance of M-values. Top row: CpG-wise variances of M-values
were calculated. Then the values were ordered from low to high variance, grouped together in bins of
300 CpGs, and plotted against the mean M-value maintaining the ordering by variance, to see if variance
is evenly distributed across M-values. Middle row: Scatterplots of the original data values, including
the binned data points from the plots in the first row (filled circles). Bottom row: Scatterplots of the
original data values, with a lowess regression line.
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Figure SF16: Mean M-values versus variance of M-values in positive M-values (≥ 0). Top row: CpG-
wise variances of M-values were calculated. Then the values were ordered from low to high variance,
grouped together in bins of 300 CpGs, and plotted against the mean M-value maintaining the ordering by
variance, to see if variance is evenly distributed across M-values. Middle row: Scatterplots of the original
data values, including the binned data points from the plots in the first row (filled circles). Bottom row:
Scatterplots of the original data values, with a lowess regression line.
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Figure SF17: Mean M-values versus variance of M-values in negative M-values (< 0). Top row: CpG-
wise variances of M-values were calculated. Then the values were ordered from low to high variance,
grouped together in bins of 300 CpGs, and plotted against the mean M-value maintaining the ordering by
variance, to see if variance is evenly distributed across M-values. Middle row: Scatterplots of the original
data values, including the binned data points from the plots in the first row (filled circles). Bottom row:
Scatterplots of the original data values, with a lowess regression line.
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Figure SF18: Mean M-values versus MV. Top row: CpG-wise MV-scores were calculated. Then the
values were ordered from low to high MV, grouped together in bins of 300 CpGs, and plotted against
the mean M-value maintaining the ordering by MV, to see if the MV-score is evenly distributed across
M-values. Middle row: Scatterplots of the original data values, including the binned data points from
the plots in the first row (filled circles). Bottom row: Scatterplots of the original data values, with a
lowess regression line.
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Figure SF19: Mean M-values versus MV in positive M-values (≥ 0). Top row: CpG-wise MV-scores were
calculated. Then the values were ordered from low to high MV, grouped together in bins of 300 CpGs,
and plotted against the mean M-value maintaining the ordering by MV, to see if the MV-score is evenly
distributed across M-values. Middle row: Scatterplots of the original data values, including the binned
data points from the plots in the first row (filled circles). Bottom row: Scatterplots of the original data
values, with a lowess regression line.
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Figure SF20: Mean M-values versus MV in negative M-values (< 0). Top row: CpG-wise MV-scores
were calculated. Then the values were ordered from low to high MV, grouped together in bins of 300
CpGs, and plotted against the mean M-value maintaining the ordering by MV, to see if the MV-score
is evenly distributed across M-values. Middle row: Scatterplots of the original data values, including
the binned data points from the plots in the first row (filled circles). Bottom row: Scatterplots of the
original data values, with a lowess regression line.
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Figure SF21: Mean expression values versus MAD. Top row: Gene-wise MAD-values were calculated.
Then the values were ordered from low to high MAD, grouped together in bins of 100 genes, and plotted
against mean expression log counts maintaining the ordering by MAD-values, to see if the MAD is evenly
distributed across expression levels. Middle row: Scatterplots of the original data values, including the
binned data points from the plots in the first row (filled circles). Bottom row: Scatterplots of the original
data values, with a lowess regression line.
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Figure SF22: Distribution of expression values in the three cell types. Top row: Normalized gene
expression values in log counts, only protein coding genes. Bottom row: The same as above, after the
filtering applied for the analysis of differential variability, removing all genes with no reads in more than
50% of the samples in one or more of the groups (see section 3.2.5).
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Figure SF23: Mean expression values versus EV. Top row: Gene-wise EV-values were calculated. Then
the values were ordered from low to high EV, grouped together in bins of 100 genes, and plotted against
mean expression log counts maintaining the ordering by EV-values, to see if the EV is evenly distributed
across expression levels. Middle row: Scatterplots of the original data values, including the binned data
points from the plots in the first row (filled circles). Bottom row: Scatterplots of the original data values,
with a lowess regression line.
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Figure SF24: Distribution of mean expression and expression variability measurements in the three cell
types. Left: Mean expression levels (see also supplementary figure SF22). Middle: MAD-values of
expression. Right: EV-values of expression.
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Figure SF25: Scatterplots of mean expression levels marking genes with differential DNA methylation
variability. Every data point represents a gene. The colors correspond to the genomic region to which
the hypervariably methylated CpGs of the genes belong. The dotted line represents the identity line.
The three different pair-wise comparisons of the three groups are shown in columns. Top row: Genes
with increased DNA methylation variability in the first group are marked. Bottom row: Genes with
increased DNA methylation variability in the second group are marked.
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Figure SF26: Scatterplots of EV-scores marking genes with differential DNA methylation variability.
Every data point represents a gene. The colors correspond to the genomic region to which the hyper-
variably methylated CpGs of the genes belong. The dotted line represents the identity line. The three
different pair-wise comparisons of the three groups are shown in columns. Top row: Genes with increased
DNA methylation variability in the first group are marked. Bottom row: Genes with increased DNA
methylation variability in the second group are marked.
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Figure SF27: Boxplots of mean expression levels and EV-scores comparing genes with cell type specific
differential DNA methylation variability to others and across cell types. Left column: Genes with cell
type specific DNA methylation variability in monocytes in either their promoters or gene bodies are
plotted beside the rest of the genes for all three cell types. Middle column: Genes with cell type specific
DNA methylation variability in neutrophils in either their promoters or gene bodies are plotted beside
the rest of the genes for all three cell types. Right column: Genes with cell type specific DNA methylation
variability in T cells in either their promoters or gene bodies are plotted beside the rest of the genes
for all three cell types. Top row: Mean expression levels are compared. Bottom row: EV-scores are
compared.
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Figure SF28: Global relationship between promoter methylation variability and gene expression. MV-
values were plotted against the mean expression values or against the EV. First two rows: Scatterplots
of the original values, including the binned data points from figure 4.22 (filled circles). Last two rows:
Scatterplots of the original data values, with a lowess regression line.
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Figure SF29: Global relationship between gene body methylation variability and gene expression. MV-
values were plotted against the mean expression values or against the EV. First two rows: Scatterplots
of the original values, including the binned data points from figure 4.23 (filled circles). Last two rows:
Scatterplots of the original data values, with a lowess regression line.
175
Annex II
Publications

Publications Forming Part of the Thesis
Kulis M, Heath S, Bibikova M, Queiros AC et al. 2012. Epigenomic analysis detects
widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat
Genet 44(11), pp. 1236-42.
Ferreira PG et al. 2014. Transcriptome characterization by RNA sequencing identifies a
major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res
24(2), pp. 212-26.
Ecker S, Pancaldi V et al. 2015. Higher gene expression variability in the more aggressive
subtype of chronic lymphocytic leukemia. Genome Med 7(1), p. 8.
Kulis M et al. 2015. Whole-genome fingerprint of the DNA methylome during human
B-cell differentiation. Nat Genet 47(7), pp. 746-56.
